<SEC-DOCUMENT>0001683168-21-001870.txt : 20210511
<SEC-HEADER>0001683168-21-001870.hdr.sgml : 20210511
<ACCEPTANCE-DATETIME>20210510210743
ACCESSION NUMBER:		0001683168-21-001870
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210510
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210511
DATE AS OF CHANGE:		20210510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RadNet, Inc.
		CENTRAL INDEX KEY:			0000790526
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				133326724
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33307
		FILM NUMBER:		21909288

	BUSINESS ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025
		BUSINESS PHONE:		3104787808

	MAIL ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIMEDEX HEALTH SYSTEMS INC
		DATE OF NAME CHANGE:	19930518

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCC FRANCHISING CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>radnet_i8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:RDNT="http://radnet.com/20210510">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_RDNT_radnet.com_20210510 -->
<!-- Field: Set; Name: xdx; ID: xdx_041_20210510_20210510_zwxPeeCcnueg -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0000790526 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-05-10to2021-05-10" name="dei:EntityCentralIndexKey">0000790526</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-05-10to2021-05-10" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rdnt-20210510.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-05-10to2021-05-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000790526</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-10</xbrli:startDate>
        <xbrli:endDate>2021-05-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_901_edei--DocumentType_c20210510__20210510_z5teT5HhCJwg"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 OR 15(d) of The
Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):&#160;
<b><span id="xdx_90A_edei--DocumentPeriodEndDate_c20210510__20210510_zLYs1cWTmvR"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">May 10, 2021</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityRegistrantName_c20210510__20210510_zMevxLHR927l"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" name="dei:EntityRegistrantName">RadNet, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 34%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20210510__20210510_zSNexrxDZWv4"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_900_edei--EntityFileNumber_c20210510__20210510_zkmdv936Jaif"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" name="dei:EntityFileNumber">001-33307</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20210510__20210510_zHR0lGXQEI51"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" name="dei:EntityTaxIdentificationNumber">13-3326724</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</p></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 50%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20210510__20210510_zPekY1ycI8X9"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" name="dei:EntityAddressAddressLine1">1510 Cotner Avenue</ix:nonNumeric></span><br />
<span id="xdx_902_edei--EntityAddressCityOrTown_c20210510__20210510_zbijj3RDfjbe"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" name="dei:EntityAddressCityOrTown">Los Angeles</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20210510__20210510_zIEQvDEtiZYf"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_900_edei--EntityAddressPostalZipCode_c20210510__20210510_zKc8gnmp6iH3"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" name="dei:EntityAddressPostalZipCode">90025</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code:&#160;<b><span id="xdx_908_edei--CityAreaCode_c20210510__20210510_z38qZm5Nyvdh"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" name="dei:CityAreaCode">(310)</ix:nonNumeric></span> <span id="xdx_905_edei--LocalPhoneNumber_c20210510__20210510_zEFArUUAoBp1"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" name="dei:LocalPhoneNumber">478-7808</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--WrittenCommunications_c20210510__20210510_z3Q90moZZh93"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="width: 98%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--SolicitingMaterial_c20210510__20210510_zKyahoUzjpq2"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="width: 98%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--PreCommencementTenderOffer_c20210510__20210510_z9bqBVcw1Vmk"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="width: 98%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--PreCommencementIssuerTenderOffer_c20210510__20210510_zenmnxNylnt1"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="width: 98%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 31%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title&#160;of&#160;each&#160;class</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 31%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading&#160;Symbol(s)</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 36%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--Security12bTitle_c20210510__20210510_zTUIT8NQH3D6"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" name="dei:Security12bTitle">Common Stock, $0.0001 par value</ix:nonNumeric></span> </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--TradingSymbol_c20210510__20210510_zPYLySU8cBi5"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" name="dei:TradingSymbol">RDNT</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--SecurityExchangeName_c20210510__20210510_zb8JKuxQ5Jmk"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#160;<span id="xdx_902_edei--EntityEmergingGrowthCompany_c20210510__20210510_zhahFJYkV7T8"><ix:nonNumeric contextRef="From2021-05-10to2021-05-10" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">&#160;</td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in">Item 2.02</td><td>RESULTS OF OPERATIONS AND FINANCIAL CONDITION</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 10, 2021 RadNet, Inc.
(&#8220;RadNet&#8221;) issued a press release and held a conference call regarding our financial results for the quarter ended March 31,
2021. A copy of the press release is furnished as Exhibit 99.1 and a copy of the transcript of the conference call is furnished as Exhibit
99.2 to this Current Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in this Current
Report, including Exhibit 99.1 and Exhibit 99.2 is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section
18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report,
including Exhibit 99.1 and Exhibit 99.2 shall not be incorporated by reference into any registration statement or other document filed
with the Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 9.01</b></td><td style="text-align: justify"><b>FINANCIAL STATEMENTS AND EXHIBITS.</b></td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-weight: normal"><span style="text-decoration: underline">Exhibit Number</span></span></td>
  <td style="padding-left: 10pt; text-indent: -10pt"><span style="text-decoration: underline">Description of Exhibit</span></td></tr>
<tr style="vertical-align: top">
  <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
  <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="padding-left: 10pt; text-indent: -10pt; width: 15%"><span style="font-weight: normal">99.1</span></td>
  <td style="text-align: left; width: 85%"><span style="font-weight: normal"><a href="radnet_ex9901.htm">Press Release dated May 10, 2021 relating to RadNet, Inc.&#8217;s financial results for the quarter ended March 31, 2021.</a></span></td></tr>
<tr style="vertical-align: top">
  <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
  <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-weight: normal">99.2</span></td>
  <td style="padding-left: 10pt; text-indent: -10pt"><a href="radnet_ex9902.htm">Transcript of conference call.</a></td></tr>
<tr style="vertical-align: top">
  <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
  <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="padding-left: 10pt; text-indent: -10pt">104</td>
  <td style="padding-left: 10pt; text-indent: -10pt">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif"><b>RADNET, INC.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 62%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 35%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Date: May 10, 2021</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Mark Stolper</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Mark Stolper</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6PbQbOnGXDhVxigwRb4vLpLg1I60/eyTf0rohhkBIzvlyhAjFmla6RobzosjhiE1bK4dQYIWM5oLekW22KfhZ4FVbx8q4fv2BGXkGPTMdzZS/986HtlimICdjmYzjCOQ8jRM47ETw1TMylS7ROK1qUKaEA1PLGp3ibvhwVC8y1HR90gnZajIpRCM5yG+IZRTDnh7qSXyzkOeZCMK+ArFmurffmLt11MCyxsZn2QH9d/AB4nVJIQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>radnet_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;<IMG SRC="image_001.jpg" ALT="" STYLE="height: 86px; width: 200px"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR IMMEDIATE RELEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 12pt"><B>RadNet Reports First Quarter Financial
Results, Including Record First Quarter Revenue, Adjusted EBITDA<I><SUP>(1)</SUP></I> and Net Income, and Revises Upwards 2021 Financial
Guidance Ranges</B></FONT><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Revenue increased 12.0% to $315.3 million in the first quarter of 2021
from $281.6 million in the first quarter of 2020</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Adjusted EBITDA<SUP>(1)</SUP> increased 123.4% to $45.5 million in the
first quarter of 2021 from $20.4 million in the first quarter of 2020; Adjusting for $6.2 million of grants received under the CARES Act
Provider Relief Fund during the quarter, Adjusted EBITDA<SUP>(1)</SUP> was $39.3 million during the first quarter of 2021 (an increase
of 92.8% from the first quarter of 2020)</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Diluted Net Income per share was $0.18 in the first quarter of 2021 as
compared with diluted net loss per share of $(0.33) from the prior year&rsquo;s first quarter; Adjusting for extraordinary items impacting
Net Income in the quarter, including grants under the Cares Act, the financial impact of our cash flow hedge and one-time COVID-19-related
retention bonuses paid to team members and physicians, diluted Adjusted Earnings Per Share<SUP>(3)</SUP> was $0.04 during the first quarter
of 2021</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Aggregate procedural volumes increased 8.4%; Same-center procedural volumes
increased 5.0% compared to the first quarter of 2020</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Subsequent to quarter end, RadNet received FDA clearance for its DeepHealth
AI mammography triage software and completed a refinancing transaction of its senior credit facilities </I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>RadNet revises full-year 2021 guidance levels to increase Revenue, Adjusted
EBITDA<SUP>(1)</SUP> and Free Cash Flow ranges</I></FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LOS ANGELES, California, May 10, 2021 &ndash;
RadNet, Inc. (NASDAQ: RDNT),</B> <FONT STYLE="color: black">a national leader in providing high-quality, cost-effective, fixed-site outpatient
diagnostic imaging services through a network of 346 owned and/or operated outpatient imaging centers</FONT>, today reported financial
results for its first quarter of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Howard Berger, President and Chief Executive
Officer of RadNet, commented, &ldquo;Despite some disruptive winter weather conditions in February on the east coast, we produced record
first quarter results. Our Revenue, Adjusted EBITDA<SUP>(1)</SUP> and Net Income performance was stronger than any other first quarter
in our company&rsquo;s history. Revenue increased 12% and Adjusted EBITDA<SUP>(1)</SUP> more than doubled from last year&rsquo;s first
quarter. Furthermore, even after adjusting for the impact of a variety of extraordinary items in the quarter such as stimulus money we
received, a substantial valuation gain on our interest rate swaps and one-time COVID-19-related retention bonuses paid to team members
and physicians, we had record first quarter earnings per share in a quarter that is typically our most challenging seasonal quarter.&rdquo;</P>

<P STYLE="color: red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Berger continued, &ldquo;Our performance was
the result of the combination of cost savings measures that we instituted during the COVID-19 period, certain investments we made (particularly
in 3D mammography) and the return to more normalized procedural volumes as the states in which we operate began to loosen COVID-19 restrictions.
COVID-19 has also been a catalyst for tuck-in acquisitions. In February and March, we completed ten center acquisitions on the east coast,
which we expect to contribute to the performance of the remaining quarters of this year.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Given the positive trends we are experiencing
in our business and the strong financial performance of the first quarter, we have elected to revise our guidance levels upwards in anticipation
of financial results that we project to exceed our original expectations. We have increased 2021 guidance ranges for Revenue, Adjusted
EBITDA<SUP>(1)</SUP> and Free Cash Flow. We also reduced our Cash Interest Expense guidance range to reflect the lower interest cost from
our recently completed refinancing transaction,&rdquo; added Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Berger continued, &ldquo;On April 19<SUP>th</SUP>,
we announced that we received FDA clearance for our DeepHealth AI mammography triage software, Saige-Q<SUP>TM</SUP>, which is a worklist
prioritization tool that enables radiologists to more effectively manage their mammography cases with the use of artificial intelligence.
The software identifies suspicious screening exams that may need prioritized attention, allowing radiologists to optimize their workflow
for efficiency and accuracy. We are at the beginning stages of deploying this technology across our various markets and expect that most
of our breast imagers will have the benefit of this AI before year end. We expect RadNet will benefit from productivity enhancements,
while providing our patients and payors with more accurate interpretations, fewer unnecessary patient call-backs and the possibility of
detecting breast disease one to two years earlier than otherwise possible.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Lastly, in April, we completed a successful
refinancing transaction of our senior term loan and revolving credit facility. Based upon our current and anticipated future leverage
ratio, we anticipate an annual interest cost savings of up to $6 million, and we have secured significantly increased financial and operating
flexibility to grow our business and execute our business plan,&rdquo; added Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first quarter of 2021, RadNet reported
Revenue of $315.3 million, Adjusted EBITDA<SUP>(1)</SUP> of $45.5 million and Net Income of $9.5 million. Revenue increased $33.8 million
(or 12.0%), Adjusted EBITDA<SUP>(1)</SUP> increased $25.1 million (or 123.4%) and Net Income increased $25.8 million over the first quarter
of 2020. Per share <FONT STYLE="color: black">Net Income for the first quarter was $0.18, compared to a per share Net Loss of $(0.33)
in the first quarter of 2020, based upon a weighted average number of diluted shares outstanding of 52.8 million shares in 2021 and 50.3
million shares in 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">There were a number
of extraordinary items impacting the first quarter including $6.2 million of grants received under the CARES Act Provider Relief Fund,
$10.0 million net gain related to cash flow hedges and $6.8 million of </FONT>COVID-19-related retention bonuses paid to team members
and physicians<FONT STYLE="color: black">. Adjusted to remove the CARES Act stimulus money received, Adjusted EBITDA</FONT><SUP>(1)</SUP>
<FONT STYLE="color: black">was $39.3 million during the first quarter of 2021 (an increase of 92.8% from the first quarter of 2020). Adjusting
for all of the above extraordinary items, Adjusted Earnings<SUP>(3)</SUP> was $2.3 million and diluted Adjusted Earnings Per Share<SUP>(3)</SUP>
was $0.04 during the first quarter of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">In addition to the
extraordinary items mentioned above, affecting Net Income in the first quarter of 2021 were certain non-cash expenses and non-recurring
items including: $8.2 million of non-cash employee stock compensation expense resulting from the vesting of certain options and restricted
stock; </FONT>$285,000 of severance paid in connection with headcount reductions related to cost savings initiatives; and <FONT STYLE="color: black">$1.1
million of non-cash amortization of deferred financing costs and loan discounts related to financing fees paid as part of our existing
credit facilities. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first quarter of 2021, as compared to
the prior year&rsquo;s first quarter, MRI volume increased 6.9%, CT volume increased 9.5% and PET/CT volume increased 2.5%. Overall volume,
taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 8.4% over the prior
year&rsquo;s first quarter. On a same-center basis, including only those centers which were part of RadNet for both the first quarters
of 2021 and 2020, MRI volume increased 2.5%, CT volume increased 4.4% and PET/CT volume increased 2.9%. Overall same-center volume, taking
into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 5.0% over the prior year&rsquo;s
same quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>2021 Revised Guidance</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RadNet amends its previously announced guidance
levels as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 30%">&nbsp;</TD>
    <TD STYLE="width: 26%"><FONT STYLE="font-size: 10pt"><U>Original Guidance Range</U></FONT></TD>
    <TD STYLE="width: 44%"><FONT STYLE="font-size: 10pt"><U>Revised Guidance Range</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Total Net Revenue</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$1,250 million - $1,300 million</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$1,275 million - $1,325 million</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Adjusted EBITDA</FONT><SUP>(1)</SUP></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$180 million - $190 million</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$187 million - $197 million</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Capital Expenditures</FONT><SUP>(a)</SUP></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$70 million - $75 million</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$72 million - $77 million</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Cash Interest Expense</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$39 million - $44 million</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$35 million - $40 million</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Free Cash Flow</FONT> <SUP>(b)(2)</SUP></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$60 million - $70 million</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$70 million - $80 million</FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Net of proceeds from the sale of equipment, imaging centers and joint venture interests, and excludes
New Jersey Imaging Network capital expenditures.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Defined by the Company as Adjusted EBITDA<SUP>(1)</SUP> less Capital Expenditures and Cash Paid for Interest.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Dr. Berger highlighted,
&ldquo;We have increased our guidance ranges for Revenue, Adjusted EBITDA</FONT><FONT STYLE="color: black"><SUP>(1)</SUP></FONT> <FONT STYLE="font-size: 10pt">and
Free Cash Flow</FONT> <FONT STYLE="color: black"><SUP>(2)</SUP></FONT><FONT STYLE="font-size: 10pt">. Additionally, with the lower interest
cost as a result of our recent refinancing transaction, we have decreased our Cash Interest Expense guidance range.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call for Today</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Howard Berger, President and Chief Executive
Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its first quarter
2021 results on Monday, May 10th, 2021 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Conference Call Details:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: Monday, May 10, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Time: 10:30 a.m. Eastern Time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dial In-Number: 800-437-2398</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">International Dial-In Number: 929-477-0577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is recommended that participants dial in approximately
5 to 10 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts available at http://public.viavid.com/index.php?id=144796
or http://www.radnet.com under the &ldquo;Investors&rdquo; menu section and &ldquo;News Releases&rdquo; sub-menu of the website. An archived
replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international
callers, and using the passcode 2257200.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>About RadNet, Inc.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RadNet, Inc. is the leading national provider of freestanding, fixed-site
diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of
346 owned and/or operated outpatient imaging centers. RadNet's core markets include California, Maryland, Delaware, New Jersey, New York
and Arizona. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total
of approximately 8,300 employees. For more information, visit http://www.radnet.com.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>Forward Looking Statements</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and
strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified
by words such as: &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;goal,&rdquo; &ldquo;seek,&rdquo; &ldquo;believe,&rdquo;
&ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;strategy,&rdquo; &ldquo;future,&rdquo; &ldquo;likely,&rdquo;
&ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;will&rdquo; and similar references to future periods. Forward-looking statements in this
press release include, among others, statements we make regarding response to and the expected future impacts of COVID-19, including statements
about our anticipated business results, balance sheet and liquidity and our future liquidity, burn rate and our continuing ability to
service or refinance our current indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">Forward-looking statements are neither historical
facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties,
risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and
financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue
reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to
differ materially from those indicated in the forward-looking statements include, among others, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the ongoing impact of the COVID-19 pandemic on
our business, suppliers, payors, customers, referral sources, partners, patients and employees, including (i) government&rsquo;s unprecedented
action regarding existing and potential restrictions and/or obligations related to citizen and business activity to contain the virus;
(ii) the consequences of an economic downturn resulting from the impacts of COVID-19 and the possibility of a global economic recession;
(iii) the impact of the volume of canceled or rescheduled procedures, whether as a result of government action or patient choice; (iv)
measures we are taking to respond to the COVID-19 pandemic, including changes to business practices; (v) the impact of government and
administrative regulation, guidance and appropriations; (vi) changes in our revenues due to declining patient procedure volumes, changes
in payor mix; (vii) potential increased expenses or workforce disruptions related to our employees that could lead to unavailability of
key personnel; (viii) workforce disruptions related to our key partners, suppliers, vendors and others we do business with; (ix) the impact
of return to work orders in certain states in which we operate; and (x) increased credit and collectability risks;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the availability and terms of capital to fund
our business;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to service our indebtedness, make
principal and interest payments as those payments become due and remain in compliance with applicable debt covenants, in addition to our
ability to refinance such indebtedness on acceptable terms;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in general economic conditions nationally
and regionally in the markets in which we operate;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the availability and terms of capital to fund
the expansion of our business and improvements to our existing facilities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to maintain our current credit rating
and the impact on our funding costs and competitive position if we do not do so;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">volatility in interest and exchange rates, or
credit markets;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the adequacy of our cash flow and earnings to
fund our current and future operations;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in service mix, revenue mix and procedure
volumes; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in receiving payments for services provided;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">increased bankruptcies among our partner physicians
or joint venture partners;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the impact of the political environment and related
developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act;
</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the extent to which the ongoing implementation
of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof by federal and state regulators or
related litigation result in a reduction in coverage or reimbursement rates for our services, or other material impacts to our business;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">closures or slowdowns and changes in labor costs
and labor difficulties, including stoppages affecting either our operations or our suppliers' abilities to deliver supplies needed in
our facilities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the occurrence of hostilities, political instability
or catastrophic events; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the emergence or reemergence of and effects related
to future pandemics, epidemics and infectious diseases; and </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">noncompliance by us with any privacy or security
laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation, loss or other unauthorized
use or disclosure of confidential information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any forward-looking statement contained in this
current report is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation
to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of
changed circumstances, new information, future developments or otherwise, except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulation G: GAAP and Non-GAAP Financial
Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release contains certain financial information
not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes
that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes
this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in
the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should
not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled
measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial
information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this
release in the tables which follow.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>CONTACTS: </I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>RadNet, Inc.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Mark Stolper, 310-445-2800</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Executive Vice President and Chief Financial
Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2020</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">31,091</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">102,018</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146,665</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129,585</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Due from affiliates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,521</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,836</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">37,720</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,985</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">222,997</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">270,424</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">412,711</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">399,335</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Operating lease right-of-use assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">529,563</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">483,661</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Total property, equipment and right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">942,274</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">882,996</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OTHER ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">502,566</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">472,879</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Other intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,198</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,393</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,590</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,767</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Investment in joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,813</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,528</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Deferred tax assets, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,554</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,687</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Deposits and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">38,794</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">36,983</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,828,786</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,786,657</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: center">LIABILITIES AND EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Accounts payable, accrued expenses and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">231,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">236,684</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Due to affiliates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,133</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,010</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,648</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,257</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Current finance lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,578</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Current operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,890</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,794</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Current portion of notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">40,166</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">39,791</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">402,617</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">398,114</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">LONG-TERM LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Long-term finance lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">414</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">743</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Long-term operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">504,474</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">463,096</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Notes payable, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">602,684</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">612,913</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Other non-current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">37,239</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">53,488</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,547,428</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,528,354</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">RadNet, Inc. stockholders' equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock - $.0001 par value, 200,000,000 shares authorized; 51,640,537 and 52,340,856 shares issued and outstanding at December 31, 2020 and March 31, 2021, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Additional paid-in-capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">316,032</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">307,788</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Accumulated other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,138</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,051</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(108,541</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(117,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Total RadNet, Inc.'s stockholders' equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">184,358</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">165,743</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">97,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">92,560</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">281,358</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">258,303</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,828,786</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,786,657</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">REVENUE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Service fee revenue</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">279,577</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">248,333</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Revenue under capitation arrangements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,742</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">33,231</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Total service revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315,319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">281,564</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Provider relief funding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,248</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Cost of operations, excluding depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">282,280</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">267,417</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,656</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,934</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">(Gain) loss on sale and disposal of equipment and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,307</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">771</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Severance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">285</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">218</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: 400; font-style: normal; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">303,914</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">290,340</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">INCOME (LOSS) FROM OPERATIONS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,653</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,776</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">OTHER INCOME AND EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,552</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Equity in earnings of joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,285</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,955</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,245</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Other expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">206</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Total other (income) expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(498</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,603</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">INCOME (LOSS) BEFORE INCOME TAXES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,151</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,379</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">(Provision for) benefit from income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,376</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,381</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">NET INCOME (LOSS)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,775</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,998</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Net income attributable to noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,317</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,360</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,458</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(16,358</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.33</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.33</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">WEIGHTED AVERAGE SHARES OUTSTANDING</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">51,951,506</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,294,329</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">52,828,941</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,294,329</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net income (loss)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">13,775</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(13,998</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Adjustments to reconcile net income&nbsp;&nbsp;(loss) to net cash provided by operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,656</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,934</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Amortization of operating lease assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,863</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,259</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Equity in earnings of joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,285</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,955</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Amortization deferred financing costs and loan discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,081</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">(Gain) loss on sale and disposal of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,307</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">771</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Amortization of cash flow hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">925</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,245</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,248</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,622</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Change in fair value of contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,493</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,504</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,308</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,164</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,507</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">677</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Deferred taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,133</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,413</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Operating leases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,291</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,345</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,416</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Accounts payable, accrued expenses and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,157</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21,584</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 40pt">Net cash provided by operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">40,913</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Purchase of imaging facilities and other acquisitions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(57,075</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,300</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,424</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51,538</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from sale of equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">151</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">779</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 40pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(87,348</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(55,059</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Principal payments on notes and leases payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(827</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(914</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Payments on Term Loan Debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,824</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,824</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from revolving credit facility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">215,900</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Payments on revolving credit facility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(87,100</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(135,900</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 40pt">Net cash (used in) provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,651</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">68,262</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">EFFECT OF EXCHANGE RATE CHANGES ON CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">NET INCREASE IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(70,927</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,117</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">CASH AND CASH EQUIVALENTS, beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">102,018</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">40,165</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">CASH AND CASH EQUIVALENTS, end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">31,091</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">94,282</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Cash paid during the period for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,267</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,934</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0; text-align: center; background-color: white"><B>RADNET,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0; text-align: center; background-color: white"><B>RECONCILIATION
OF GAAP NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA<SUP>(1)</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>(IN THOUSANDS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Net income (loss) attributable to RadNet, Inc. common stockholders</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">9,458</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(16,358</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Provision for (benefit from) income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,376</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,381</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,552</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Severance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,656</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,934</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Non-cash employee stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,248</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,622</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">(Gain) loss on sale and disposal of equipment and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,307</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">771</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,245</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">206</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; font-style: normal; padding-bottom: 2.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700"><SUP>(1)</SUP></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">45,503</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">20,364</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PAYOR CLASS BREAKDOWN</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 62%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">First Quarter</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 45%; text-align: left">Commercial Insurance</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">59.3%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Medicare</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20.2%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Capitation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.3%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Medicaid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.7%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Workers Compensation/Personal Injury</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.3%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3.3%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET PAYMENTS BY
MODALITY</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">First Quarter</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 32%">MRI</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">35.1%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">35.4%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">35.8%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">35.2%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.4%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.6%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.9%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.5%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>PET/CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.7%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.6%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.7%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>X-ray</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.9%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.3%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.1%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.4%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Ultrasound</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.9%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.3%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.4%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.2%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Mammography</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.6%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.7%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.2%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.8%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Nuclear Medicine</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.3%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.7%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.9%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.1%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U><BR STYLE="clear: both">
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Footnotes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><SUP>(1)</SUP>
The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations
and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation.
Adjusted EBITDA</FONT> includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling
interests in subsidiaries<FONT STYLE="color: windowtext">, and is adjusted for non-cash or extraordinary and one-time events taken place
during the period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted EBITDA is reconciled to its nearest comparable
GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare
industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not
be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation
or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data
presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a
measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented,
may not be comparable to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><SUP>(2)</SUP>
As noted above, the Company defines Free Cash Flow as </FONT>Adjusted EBITDA less total Capital Expenditures (whether completed with cash
or financed) and Cash Interest paid. <FONT STYLE="color: windowtext">Free Cash Flow is a non-GAAP financial measure. </FONT>The Company
uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity
to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows
generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Free Cash Flow should not be considered a measure
of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives
to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the
consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined
in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable
to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SCHEDULE OF ADJUSTED EARNINGS AND EARNIGNS PER SHARE<FONT STYLE="font: normal 700 10pt Times New Roman, Times, Serif"><SUP>(3)</SUP></FONT></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE DATA)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp; &nbsp; &nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Three Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 83%; font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET INCOME ATRRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,458</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Subtract provider relief funding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,248</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Subtract non-cash net gain from cash flow hedges (i)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Add COVID-19-related retention bonuses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,839</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;Total adjustments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,409</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Subtract tax impact of adjustments (ii)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,258</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;Tax effected impact of adjustments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,151</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL ADJUSTMENT TO NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(7,151</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">ADJUSTED NET INCOME ATRRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,307</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold">WEIGHTED AVERAGE SHARES OUTSTANDING</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,828,941</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">ADJUSTED DILUTED NET INCOME PER SHARE ATRRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.04</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(i) Impact is the combination of (a) the change
in fair value of the hedges during the quarter and (b) the amortization of the accumulation of the changes in fair value from Other Comprehensive
Income that existed prior to the hedges becoming ineffective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(ii) Tax effected using 24.0% blended federal and state effective tax rate.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>radnet_ex9902.htm
<DESCRIPTION>CONFERENCE CALL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.2</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>C O R P O R A T E P A R T I
C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper, </B><I>Executive Vice President
and Chief Financial Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger, </B><I>Chairman, President
and Chief Executive Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>C O N F E R E N C E C A L L
P A R T I C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut, </B><I>Jefferies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom, </B><I>Raymond James</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>P R E S E N T A T I O N</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good day, and welcome to the RadNet Inc. First
Quarter Financial Results Call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today's conference is being recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I would like to turn the conference
over to Mr. Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet, Inc. Please go ahead, sir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, ladies and gentlemen, and thank
you for joining Dr. Howard Berger and me today to discuss RadNet's First Quarter 2021 Financial Results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we begin today, we'd like to remind everyone
of the Safe Harbor statement under the Private Securities Litigation Reform Act of 1995. This presentation contains forward-looking statements
within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning anticipated future
financial and operating performance; RadNet's ability to continue to grow the business by generating patient referrals and contracts with
radiology practices; recruiting and retaining technologists; receiving third-party reimbursement for diagnostic imaging services; successfully
integrating acquired operations; generating revenue and Adjusted EBITDA for the acquired operations as estimated, among others, are forward-looking
statements within the meaning of the Safe Harbor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are based on Management's
current preliminary expectations and are subject to risks and uncertainties which may cause RadNet's actual results to differ materially
from the statements contained herein. These risks and uncertainties, including those risks set forth in RadNet's reports filed with the
SEC from time to time, including RadNet's Annual Report on Form 10-K for the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Undue reliance should not be placed on forward-looking
statements, especially guidance on future financial performance which speaks only as of the date it is made. RadNet undertakes no obligation
to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or
to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that, I'd like to turn the call over to Dr.
Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, everyone, and thank you for joining
us today.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On today's call, Mark and I plan to provide you
with highlights from our first quarter '21 results, give you more insight into factors which affected this performance and discuss our
future strategy. After our prepared remarks, we will open the call to your questions. I'd like to thank all of you for your interest in
our Company and for dedicating a portion of your day to participate in our conference call this morning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we start, I would like to say on behalf
of myself and the entire team at RadNet, we hope all of you and your loved ones are healthy and staying safe. We are extremely grateful
for all of our stakeholders, including our employees, business partners, lenders and shareholders, and wish you all well during this challenging
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Let's begin. I'm extremely pleased with our performance
this quarter. Our financial and operating metrics in the first quarter demonstrate continued strengthening and improvement in our business
that began in the third quarter of last year and as the result of a number of factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">First, during the COVID period, we instituted
a variety of cost saving measures that have lowered operating expenses and created efficiencies within our regionally clustered centers,
cost reductions and efficiencies that will remain permanently with the business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Second, our procedural volumes have substantially
recovered as the states within which we operate have loosened COVID-19 restrictions. The result of the loosening of these restrictions
has been that patients are visiting their physicians with more regularity and are utilizing healthcare with more normalcy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lastly, investments we made last year and during
the first quarter, both with respect to capital expenditures and acquisitions, are beginning to contribute to our financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We discussed on our last financial results call
the extraordinary investment we made in upgrading our mammography systems during 2020 to 3D digital tomography&mdash;mammography, or tomosynthesis.
While we do not believe mammography volumes have fully recovered from the COVID-19 impact, we are experiencing enhanced reimbursement
from the volumes we are now performing on these newly upgraded 3D systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, during the first quarter, we acquired
10 facilities within the New York Metropolitan market. The newly acquired facilities have unique cost savings and consolidation opportunities
with existing RadNet facilities. Those new centers contributed positively to the first quarter. We expect significant improvement from
their results later in the year when we are further along with their integration processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of all of these factors, our results
were the best first quarter results in our Company's history. As compared with last year's first quarter, revenue increased 12% and EBITDA
more than 100%. I am particularly proud of the margin improvement we were able to demonstrate in the first quarter, relative to the first
quarters of 2020 and 2019. After deducting the CARES Act stimulus funds and removing the impact from the CARES Act related retention bonuses,
we achieved a 14.6% EBITDA margin in this quarter. This is an improvement from 2020's first quarter EBITDA margin of 7.2% and 2019's first
quarter EBITDA margin of 12.2%. The margin improvement is the result of many of the cost saving measures we have put in place, which have
included consolidating underperforming sites and changing key operational processes, both at the center level and within our corporate
support departments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted earnings were also very strong in this
quarter. Typically, EBITDA and profitability is challenged in the first quarter where we face seasonality as it relates to winter weather
conditions and lower utilization of healthcare services related to the annual resetting of patient deductibles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In contrast to net losses in the first quarters
of past years, this year's first quarter was profitable. We recognized net income per share during the quarter of $0.18. Adjusted to remove
the gain from our swaps, the CARES Act stimulus money and one-time COVID-related retention bonuses to employees and contracted physicians,
net income per share was $0.04. This is an increase to net losses in last year's first quarter of $0.33 and $0.08 in the first quarter
of 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the strong performance in this
year's first quarter and the confidence we are feeling for the remainder of the year, we have elected to increase most of our key financial
guidance levels for 2021. Mark in his prepared remarks will review the increases we've made to our revenue, EBITDA and free cash flow
guidance levels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is also worth noting that we decreased the
guidance levels for cash interest expense as a result of the interest cost savings from the recently completed refinancing transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As many of you might have seen, on April 26, we
announced the completion of the refinancing of our term loan and revolving line of credit. Based upon current and anticipated future leverage
ratios, we expect to save up to $6 million annually in interest expense; although we are no longer subject to restrictive maintenance
covenants with respect to our term loan, and have substantially more operating and financial flexibility under the new credit agreement.
This includes lowering our annual required amortization payments by over $30 million a year and adding over $100 million to our cash balance,
which will enable us to accelerate growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This refinancing is a meaningful achievement in
the Company's growth and development. I would like to thank all of the lenders and relationship banks for their trust and support of our
business and Executive Management team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One of the factors that drove the successful refinancing
transaction was that we've been able to achieve meaningful deleveraging of our balance sheet over the past few years. The strong performance
and conservative fiscal discipline has enabled us to achieve a leverage ratio of 3.7 times net debt to trailing 12 month EBITDA as of
March 31, 2021. Pro forma for the recent acquisition, this ratio is even lower, which is indicative of further expected deleveraging in
the upcoming quarters. While we are committed to growing and expanding our business, we will also continue to follow our methodical and
disciplined approach to managing our financial leverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lastly, and before I hand the call over to Mark,
I'd like to discuss the recent success in the area of artificial intelligence. On April 19, we announced that our artificial intelligence
subsidiary DeepHealth received FDA clearance for its AI mammography triage software Saige-Q.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Saige-Q is a screening worklist prioritization
tool that enables radiologists to more effectively manage their mammography cases with the use of artificial intelligence. DeepHealth&rsquo;s
powerful new AI technology automatically identifies suspicious screening exams that may need prioritized attention, allowing radiologists
to optimize their workflow for efficiency and accuracy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This technology is the first FDA cleared mammography
triage product that supports both 3D and 2D mammography images. This FDA clearance is an important step in RadNet's commitment to delivering
the best quality of care to our patients. With almost 2 million mammography exams, which we will be performing annually in our markets,
we have now begun to deploy this tool, enabling our mammographers to become more accurate and productive. We expect by year end that the
vast majority of our screening mammography exams will run through the Saige-Q AI engine. The efficiency gains, which we expect to exceed
25% on screening mammography exams, and accuracy, should be further enhanced by a more advanced diagnostic algorithm we plan to submit
to the FDA for its review by year end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I'd like to turn the call back over
to Mark to discuss some of the highlights of our first quarter 2021 performance. When he is finished, I will make some closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Howard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I'm now going to briefly review our first quarter
2021 performance, and attempt to highlight what I believe to be some material items. I will also give some further explanation of certain
items in our financial statements, as well as provide some insights into some of the metrics that drove our first quarter performance.
I will also provide an update to 2021 financial guidance levels, which were released in conjunction with our 2020 year-end results in
March.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In my discussion, I will use the term Adjusted
EBITDA, which is a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and
amortization, and excludes losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishments and non-cash
equity compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted EBITDA includes equity earnings in unconsolidated
operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary
and one-time events taking place during the period. A full quantitative reconciliation of Adjusted EBITDA to net income or loss attributable
to RadNet, Inc. common shareholders is included in our earnings release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that said, I'd now like to review our first
quarter 2021 results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first quarter of 2021, RadNet reported
revenue of $315.3 million, Adjusted EBITDA of $45.5 million. Revenue increased $33.8 million or 12%. Adjusted EBITDA increased $25.1 million
or 123.4%. Subtracting the $6.2 million of grants we received under the CARES Act Provider Relief Fund, Adjusted EBITDA was $39.3 million,
an increase of 92.8% from last year's first quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As Dr. Berger discussed in his remarks, the significantly
improved performance is a result of increased procedural volumes, cost reductions instituted during the COVID-19 period, additional revenue
from our migration to 3D mammography, and the contribution from tuck-in acquisitions we completed in February and March. The performance
in this quarter relative to the prior year's quarter was negatively impacted, however, by severe winter weather conditions that caused
us to temporarily close East Coast sites for several days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net income during the quarter was $9.5 million,
an increase of $25.8 million over last year's first quarter. Per share net income for the first quarter was $0.18 compared to a net loss
of negative $0.33 in the first quarter of 2020. This is based upon weighted average number of diluted shares outstanding of 52.8 million
shares in 2021 and 50.3 million shares in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were a number of extraordinary items impacting
the first quarter, including the $6.2 million of grants received under the CARES Act Provider Relief Fund, $10 million net gain related
to our cash flow hedges, and $6.8 million of employee COVID-19 related retention bonuses paid to our physicians and team members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusting for all of the above extraordinary items,
adjusted net income was $2.3 million and diluted adjusted net income per share was $0.04 during the first quarter of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the extraordinary items I just
mentioned, also affecting net income in the first quarter of 2021 were certain non-cash expenses and non-recurring items including the
following: $8.2 million of non-cash employee stock compensation expense resulting from the vesting of certain options and restricted stock;
$285,000 of severance paid in connection with headcount reductions related to cost savings initiatives; and $1.1 million of non-cash amortization
of deferred financing costs and loan discounts related to financing fees paid as part of our existing credit facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first quarter of 2021, as compared to
the prior-year's first quarter, MRI volume increased 6.9%, CT volume increased 9.5% and PET/CT volume increased 2.5%. Overall volume,
taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and all other exams, increased 8.4% over the prior-year's
first quarter. On a same-center basis, including only those centers which were part of RadNet for both the first quarters of 2021 and
2020, MRI volume increased 2.5%, CT volume increased 4.4% and PET/CT volume increased 2.9%. Overall same-center volume, taking into account
routine imaging exams, increased 5.0% over the prior year same quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the first quarter of 2021, we performed 2,018,849
total procedures. The procedures were consistent with our multi-modality approach, whereby 76.7% of all the work we did by volume was
from routine imaging. Our procedures in the first quarter of 2021 were as follows: 281,096 MRIs as compared with 263,055 MRIs in the first
quarter of 2020; 178,510 CTs as compared with 163,082 CTs in the first quarter of 2020; 10,950 PET/CTs as compared with 10,683 PET/CTs
in the first quarter of 2020; and 1,548,293 routine imaging exams compared with 1,425,678 of these routine imaging exams in the first
quarter of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overall GAAP interest expense for the first quarter
of 2021 was $12.8 million. This compares with GAAP interest expense in the first quarter of 2020 of $11.6 million. Cash paid for interest
during the period, which excludes noncash deferred financing expense and accrued interest, was $8.3 million as compared with $9.9 million
in the first quarter of last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With regards to our balance sheet, as of March
31, 2021, unadjusted for bond and term loan discounts, we had $623 million of net debt, which is our total debt at par value less our
cash balance. This compares with $678.8 million of net debt at March 31, 2020. Note that these debt balances includes New Jersey Imaging
Network's debt of approximately $51.6 million, for which RadNet is neither a borrower nor a guarantor. As of March 31, 2021, we were undrawn
on our $195 million revolving line of credit and had a cash balance of $31.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As Dr. Berger noted in his prepared remarks, the
refinancing transaction that we closed in April added over $100 million of cash to our balance sheet. So we expect our cash balance reported
during our next financial results call in August will report a substantially higher cash balance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2021, our accounts receivable balance
was $146.7 million, an increase of $17.1 million from year-end 2020. The increase in accounts receivable is mainly the result of the significant
increase in our procedural volumes and revenue, particularly during the second half of March relative to 2020 revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our days sales outstanding, or DSO, remains near
the lowest levels of our Company's history. Despite increases in aggregate accounts receivable, our DSO was 36.3 days at March 31, 2021,
essentially flat from year-end 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through March 31, 2021, we had total capital expenditures
net of asset dispositions and sale of imaging center assets and joint venture interest of $30.3 million. Note that each year, we front-load
the majority of our capital decisions into the first part of the year, so cap ex is disproportionately higher in the first half of the
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I'd like to update and revise our
2021 financial year guidance levels which we released in conjunction with our fourth quarter and year-end 2020 results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For total net revenue, our original guidance range
was $1.25 billion to $1.3 billion. Our new revised guidance range is $1.275 billion to $1.325 billion. We increased both the low end and
the high end of the revenue range by $25 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For Adjusted EBITDA, our original guidance ranges
were $180 million to $190 million. We've increased both the bottom and top end of those ranges by $7 million to $187 million to $197 million.
For capital expenditures, our original guidance range was $70 million to $75 million. We increased both the bottom and the top end of
this range by $2 million to $72 million to $77 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For cash interest expense, our original guidance
range was $39 million to $44 million. Because of the success of the refinancing transaction, we lowered the cash interest expense range
to $35 million to $40 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And finally, with respect to our free cash flow,
our original guidance range was $60 million to $70 million. This year, we revised our guidance range to $70 million to $80 million. And
as a reminder, the Company defines free cash flow as Adjusted EBITDA less capital expenditures, less cash paid for interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As just noted, we have increased our financial
guidance ranges for revenue, Adjusted EBITDA and free cash flow and lowered our interest cost as a result of the refinancing transaction.
Each quarter, we reevaluate our actual and projected performance against guidance levels. We will continue to update these levels as appropriate
throughout the remainder of the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to Medicare reimbursement for 2022,
there is nothing to report at this time. As typical each year, we are expecting CMS to release a preliminary rate schedule sometime in
the June or July timeframe. At which time, we will analyze CMS' proposal and our industry's lobbying group, the Association for Quality
Imaging, will provide CMS our industry's feedback. At the time of our second quarter financial results call, we will be in a position
to comment on CMS' proposal and its impact, if any, upon RadNet's future results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I'd now like to turn the call back to Dr. Berger
who will make some closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As you likely gathered from our discussion today,
the challenges created by the COVID-19 pandemic have enabled us to become a stronger business that we believe is well positioned for future
growth and sustained profitability. COVID-19 required us to reevaluate every aspect of our business, a business that has grown substantially
in the past through acquisitions. COVID-19 allowed us to pause and analyze all of our procedures and processes in order to achieve more
optimal performance. The pandemic also gave us the opportunity to make decisions that would have proven to be more difficult in normal
times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were able to consolidate some of our centers
that were in close proximity with other centers in ways that preserve patient access, convenience and our procedural volumes. As you also
heard today, COVID-19 has also facilitated highly strategic acquisitions that may have otherwise not been available to us. As a result,
we believe that we have created a platform with infrastructure and processes to effectively manage and support a significantly larger
and more diverse business. Today, RadNet is more multifaceted than any other time in our history. We are growing our business in all of
the seven states on both coasts in which we operate, all of which have attractive demographics and a multitude of local market opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are now partnered with some of the largest
and most prestigious hospital and health systems in joint ventures that encompass approximately 25% of our facilities. We also control
our own IT infrastructure with our suite of eRAD products and services that we also sell and license to other industry participants. Furthermore,
we have made significant investments in the development of artificial intelligence, which we believe will have a transformative impact
on our business and the diagnostic imaging industry in general, particularly around the diagnostics and screening related to breast, prostate,
colon and lung diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we have tried to emphasize in today's report,
our business is healthy and growing, and we are exceeding the expectations that we originally set forth in our initial guidance levels.
Furthermore, the refinancing transaction positions us with significantly more available financial resources as a result of the over $100
million we were able to fund to our balance sheet, the lowering of our interest cost and the substantial reduction of required debt amortization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conclusion, we are excited and enthusiastic
about the opportunities that lie ahead for RadNet, and we look forward to updating you further in the upcoming quarters regarding our
progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operator, we are now ready for the question-and-answer
portion of the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. We start with Brian Tanquilut from
Jefferies. Please go ahead. Your line is open.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hey, good morning guys. Congrats on a solid quarter.
I guess, Howard, my first question for you, you talked about recovery and you mentioned mammography is one that's still kind of lagging.
So just wanted to hear your thoughts and your views on the recovery pace, how much upside left do we have to volumes going forward? And
then just any color you can share on mammography.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, Brian. Thank you. The majority of
our modalities have returned to pre-COVID levels and actually are beginning to exceed those. The one exception to that is our mammography.
And in reviewing not only our statistics but national statistics, what we saw during primarily the second quarter of the pandemic, meaning
2020, was all of our volumes decreased substantially, but the one that appeared to have the greatest impact from COVID was screening mammography.
And this should not be unexpected given that all screening mammography is elective. And during that quarter, meaning the second quarter
of last year, we saw in addition to other modalities, at one time, almost an 85% to 90% decrease in our volumes in the East Coast.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In analyzing this further, what we have determined
and I believe is not unique to RadNet, is that the annual screening mammography was essentially a disrupted cycle that, while the patients
who elected not to get their screening mammography during the second quarter of last year, have now completed that cycle, but later in
the third and fourth quarters of 2020 and the first quarter of 2021. So as a result, the three months where we saw this rather dramatic
drop-off, while there's been a return in other elective procedures, we believe that this disruption to the normal annual cycle will take
about somewhere close to the three months of this quarter to fully return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So while we're very pleased with our volumes that
we're experiencing here in the second quarter, with other areas such as diagnostic x-ray and MRI and CT have fully recovered and are actually
exceeding some of our expectations, it will probably take us a quarter for the additional screening mammography volume to return to the
same levels of growth that we have seen in the other modalities. And I believe, again, most importantly, this is not unique to RadNet.
This phenomenon with other literature and reports that we see from various sources was something that was pervasive throughout the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No, that makes a lot of sense. And then I guess,
you mentioned something on AI, right, and the developments that you've seen there. But as you think about the eventual commercialization
of AI technology and imaging and the initiatives that you've put into place there, how are you thinking about that flowing into your business,
whether it's a growth rate boost or the P&amp;L in general?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, I think that AI will have probably a more
profound impact in radiology and imaging than any other of the subspecialties. When you stop to consider that the four major cancers,
namely breast, colon, lung and prostate, are the cause of about 80% of total cancers, all four of those uniquely allow themselves to avail
from various screening procedures that we are capable of doing in our imaging centers and which patients more and more are electing not
to do in hospitals. So as the growth of AI occurs, I believe it's not just going to be something that looks at how you take various disease
processes that are more acute as you would see in hospitals, but how do we evolve much like we have in breast mammography to screening
tools that will be driven by population health management and wellness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So RadNet as a company will continue, as it has
demonstrated already, to make those kind of investments which we now are not only more capable of doing given the change in our capital
structure and the cash flow of the Company, but where we can target these much like we have in our IT platform with eRAD to areas which
we know will benefit the Company rather than by just off-the-shelf products. So I think as we implement these various tools, not only
will we be seeing, I think, a greater volume of business, but that business is going to have to be handled by artificial intelligence
in order to be able to accommodate the type of demand which we believe is on the horizon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So I'm hopeful that RadNet, as the leader in this
industry, will continue to demonstrate not just tools that perhaps make diagnoses more accurate in known disease, but really focus on
the elective side of what we do for the preponderance of our business in areas where I believe we can go directly to the insurers and
demonstrate the value proposition for breast and the other modalities that I've mentioned to begin to have them change plan design to
allow more and more of these screening tools. Because I think the benefit from this, particularly as we are demonstrating and in conversations
we're already having with some of the payors, are compelling both for cost reduction and certainly an improvement in the longevity and
morbidity that these cancers create.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So I think the ability for us to marry artificial
intelligence with our own IT platform will allow us a more rapid implementation of these tools and a more effective way for us to demonstrate
to employers, insurance companies and patients, the value of screening tools that have, other than mammography and breast cancer, not
generally been available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">That makes a lot of sense. And then I guess my
last question since you talked about your expectation of volume bolus coming up, where are the payor moves now to restrict access or shift
access away from hospital-based imaging to outpatient? We heard that during the pandemic some of that was eased a little bit, so just
curious if you're seeing payor efforts resume.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. I think there isn't a payor out there that
isn't beginning to more firmly embrace the benefits of moving volumes away from the more higher-priced hospital pricing to the outpatient
imaging sector. We're in conversations regionally with virtually all of the payors to implement tools which are both, I think, a more
aggressive effort on their parts through utilization management and scheduling to move away from hospitals. But also, I think the beginning
of the understanding on how they need to change their plan design in order to encourage more and more people to move away from hospitals.
So it doesn't matter whether you're talking about United or the Blue Cross/Blue Shields or Cigna or Aetna, I think there is an inexorable
movement which might be slow, but inevitable to, I think, create a better opportunity for patients to be screened faster and better in
outpatient settings, which they're also more comfortable going into given the pandemic and which I think will persist over years to come.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awesome. Thank you guys.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks Brian.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We take our next question from John Ransom from
Raymond James. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hey, good morning. A couple of questions. You
guys have been talking about AI, I mean, likely so for a while. But why is it reasonable to expect that to have some material effect on
your tail?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Material effect, John, on our what?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On your earnings P&amp;L, yes. When would that
show up as a kind of measurable income statement contributor?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. I think it will take probably to the latter
part of this year, John. Now that we have finally received the FDA approval on the first product, Saige-Q, we are beginning to do the
implementation across our 346 centers, most of which perform mammography. And so not only do we have a lot of centers to ramp up in the
IT infrastructure, but we have a lot of applications, both to bring our radiologists as well as technologists up to speed on the use of
these tools. If we were just dealing with a handful of centers, I would tell you that we could probably get this done in 60 to 90 days.
But with over 700 to 800 radiologists that are part of the RadNet family and probably triple that number of mammography techs, this will
be a process that we're going to do slowly and methodically because it's not just a matter of plopping our software onto their workstations,
but also making certain that we have the integrity of the IT infrastructure to manage the flow of an enormous amount of data across our
network.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So the processes that we're looking to implement
over the next 3 quarters, which we've already started, by the way, even prior to the FDA approval, will be to look at the entire infrastructure
of the Company, particularly with IT being a major focus, to make certain that the productivity gains that we hope our radiologists will
enjoy will not be limited by our ability to present them with the data on a real-time basis for interpretation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So I would say, I think these benefits towards
the latter half of this year will start bleeding through into our financials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So if we're thinking about '22, there might be
some hopefully measurable impact in the cost to read a scan now that you can look at some of those costs and take a little bit of a scalpel
to those costs as a result of this?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, I don't think it's so much taking a scalpel
to the cost of what we currently do, John. I think it's more a matter of as our volume increases, which we are very confident of in mammography,
it's allowing our radiologists to be more productive and where they're capable of handling this additional volume without us necessarily
needing to employ more radiologists to do that. We think that's a critical part of what we demonstrate not only just for RadNet, but for
the industry as a whole. If you, like we do, subscribe to the fact that perhaps as many as 40% to 50% additional mammograms should be
done annually if all of the women were complying with the current protocols for screening mammography and if we were to get all of the
women who should qualify for annual screening mammography into the system, we're talking about an enormous increase in the amount of volume
that the industry is going to have to be able to handle.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And I think that is as much of a burden and a
responsibility of RadNet to demonstrate the capability of doing that so that the system is not overwhelmed and we slow down the benefit
of getting these results into the hands of our referring physicians as rapidly as possible. So right now, RadNet does approximately 5%
of all the mammography in the United States, and we expect that to grow substantially over the next two to three years as we implement
not only artificial intelligence, but other data mining tools to improve compliance and bring women into the screening mammography process
faster and with greater confidence in the ability for us to read the screening mammography faster and earlier diagnosis of potential cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">John, just to expand on what Dr. Berger just mentioned,
the data suggests out there that there's about 40 million mammography exams completed in the United States each year. And as Dr. Berger
mentioned, the number of exams that should take place if all women age 40 and above were to be compliant with their annual screening,
would be somewhere in the neighborhood of 60 million exams or even slightly above. So that's 20 million additional exams nationally. While
we operate in states that comprise about 25% of the United States population, so if you were to apply that 25% to that 20 million of additional
exams, you're talking about another 5 million of these exams that could be performed in the markets in which we operate. So that's an
extraordinary amount of potential additional volume.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So not only will we be more productive with this
AI tool with the exams that we have in-house, but as Dr. Berger mentioned, as mammography grows in general in the industry, we'll be able
to absorb some portion of this additional volume without adding to our radiology staff. And in our tests, John, we found that our radiologists
are over 25% more productive using these AI tools, which essentially right now is a worklist tool and a prioritization tool. We think
that that number could and should go up sometime next year when our second product, which is the true mammo diagnostic product, should
be reviewed and approved by the FDA. This is going to have an extraordinary impact financially on the business, not only given current
volumes, but as we continue to grow into the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And I just found this so interesting, forgive
me if you don't want to talk it anymore, but Howard, you and I have talked about other modalities such as supplanting the current unpleasant
prostate. Is there a potential for some type of technology like this to be applied to other screening such as prostate? Or are there other
areas that I'm not thinking about excluding just the mammography opportunity?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Absolutely, John. And thank you for the question.
I think that's something you obviously personally experienced as well as a whole lot of other men. But we are working with other companies
as well as considering internally doing and making prostate MRI a screening tool which, hopefully, much like screening mammography, will
be a very rapid and effective tool for managing prostate cancer. We believe the tools that currently exist are either very costly or much
like the PSA, some PSA test, really not effective for identifying cancers early without going into a lot of other costly and cumbersome
procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So we believe these tools are within the near-term
horizon, not only for prostate. Another major focus will be for colon cancer and using CT screening, which is available now for that instead
of conventional colonoscopies. And I believe also the area of lung cancer screening, while available, is very underutilized. I've seen
statistics at only 5% to 10% of the population that would qualify for a CT scan of the lung for cancer are making themselves available
to do that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So I think imaging, much like I've said before
to a lot of people, I think imaging is the gateway to population health management, not only for cancers, but for cardiovascular disease.
And I think these are all tools that we will be working on as well as other people in the industry. And I think it could dramatically
transform the imaging industry as well as the health care industry if all of these opportunities are properly adopted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks John. Take care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It appears there are no further questions at this
time. I'd like to turn the conference back for any additional or closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Thank you, Operator. I want to, again, thank
everybody for their participation in today's call and for the support of our shareholders and employees of RadNet for their dedication
and hard work. Management will continue its endeavor to be a market leader that provides great services with an appropriate return on
investment for all stakeholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for your time today, and I look forward
to our next call. Stay safe, everyone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This concludes today's call. Thank you for your
participation. You may now disconnect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !\ 2 # 2(  A$! Q$!_\0
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M62G(T_QOH/DR$>@NK5]V?=D;Z5WFB_&7Q#H86#XC> [[PLX^]JVDS#5=+/\
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M22Z^SY_>LJ[5)R3T'% UMH6/B!_R(7B3_L&7/_HIJ_+"U_Y#/A;_ +#FF_\
MI3'7ZH?$#_D0O$G_ &#+G_T4U?E?:_\ (9\+?]AS3?\ TICIQW%+8_6ZO/\
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M<=:LTM% &3_PB>B?:1<?V-I_V@-N$WV6/>&]<XSFM VL37"SF*,S*-HD*C<
M>H!ZXJ:B@ I*6B@#Y_\ V@/V<[WQ1XLTKXJ?#>YM_#_Q=T!-D%Q-E;76K7^*
MQO,=48<*_5#@]!QZ+\(?BO9_%;PX]U]AN-"UZQD^RZSX?OP%NM,N@,M$X_B4
M]4D'RNI!!].ZKCO&'AFPM;X>+;:+[)K]E$(?M<)VFXA+#,,P_P"6B9.0#RIY
M4C)R =E13(F+1@GTI] !1110 4444 %%%% !1110 4444 %%%% !1110 444
@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>rdnt-20210510.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOa2KyaPty552SYkxvmR6fWk6bygsJZUxViRlH14W4QoJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:RDNT="http://radnet.com/20210510" elementFormDefault="qualified" targetNamespace="http://radnet.com/20210510">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://radnet.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="rdnt-20210510_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="rdnt-20210510_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>rdnt-20210510_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>rdnt-20210510_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://radnet.com/role/Cover" xlink:href="rdnt-20210510.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://radnet.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>radnet_i8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rdnt-20210510.xsd" xlink:type="simple"/>
    <context id="From2021-05-10to2021-05-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000790526</identifier>
        </entity>
        <period>
            <startDate>2021-05-10</startDate>
            <endDate>2021-05-10</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-05-10to2021-05-10">0000790526</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-05-10to2021-05-10">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-05-10to2021-05-10">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-05-10to2021-05-10">2021-05-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-05-10to2021-05-10">RadNet, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-05-10to2021-05-10">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-05-10to2021-05-10">001-33307</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-05-10to2021-05-10">13-3326724</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-05-10to2021-05-10">1510 Cotner Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-05-10to2021-05-10">Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-05-10to2021-05-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-05-10to2021-05-10">90025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-05-10to2021-05-10">(310)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-05-10to2021-05-10">478-7808</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-05-10to2021-05-10">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-05-10to2021-05-10">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-05-10to2021-05-10">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-05-10to2021-05-10">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-05-10to2021-05-10">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-05-10to2021-05-10">RDNT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-05-10to2021-05-10">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-05-10to2021-05-10">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140681838993592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 10,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RadNet, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000790526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3326724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1510 Cotner Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los Angeles<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">478-7808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RDNT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M^L_H  !*"E92L$*N@U&0/\8+ZPS4Z4]$LE-*=@K)[A')&QWE,'L<F6\S43=
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #SJ*I2!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /.H
MJE(A3B76[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( /.HJE*97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ \ZBJ4CW@\-$G
M!   (1   !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( /.HJE*?H!OPL0(  .(,   -              "
M 6H,  !X;"]S='EL97,N>&UL4$L! A0#%     @ \ZBJ4I>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  +X3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="radnet_i8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://radnet.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="radnet_i8k.htm">radnet_i8k.htm</File>
    <File>radnet_ex9901.htm</File>
    <File>radnet_ex9902.htm</File>
    <File>rdnt-20210510.xsd</File>
    <File>rdnt-20210510_lab.xml</File>
    <File>rdnt-20210510_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "radnet_i8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "radnet_i8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rdnt-20210510_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rdnt-20210510_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rdnt-20210510.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "RDNT",
   "nsuri": "http://radnet.com/20210510",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "radnet_i8k.htm",
      "contextRef": "From2021-05-10to2021-05-10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://radnet.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "radnet_i8k.htm",
      "contextRef": "From2021-05-10to2021-05-10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001683168-21-001870-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-21-001870-xbrl.zip
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M%U08, ]8/6 YSWK%Y AG00K[E6U3'!;A*Z5N[6H=0\P[FSGH[G $;Z=\2-4
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M(- P-E!&%^H%0>8-AG,_VTBUOJ.?4,,P,'F+1"7+R3T8*:U),<[QQ,K AUC
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M58GCH^&$4Z"V:CTQG8\-"Q:P4/B"J2X#0& G*I<)% [K\2BB.J,"[ZZI;:;
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M0>@=NU)=KPCHW4= ;W6G ;T["J]=A>YO/]Y<_D6E)+X,OUZ=_W]02P,$%
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M.4_BNX;H(0VAR$DG,?4VL9](5K=. )# P/U--_N-/F7E)6\^RA<=1#<$'FL
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MHTEFKB1&Y@[2L%WS#0WZ\VEJ-*_YTT&-CBYT#FK35*QQQWD"'%H#,]8XF!M
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M2\[/59T6O)C$*MT>EZ.0';;T*OOAR5DR"PA/],&I^UL<K8!0$$F1#8: G,4
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M;JP-B*8^ONHP.7+%QW",23,.A+>0WA%0B1MZ)\.@IKU^((=Q-8_"2\LL(KV
M^]F3W)8X[&( LFH&TP-L+1Y<#CNWJH>>$7(=7%-<1!G-A4$7_50V;+ (I+C(
M%,UPK_H)8ZJT2%<9C@_6F6"5>DS?"LO"P(U(@XN!?S@/SNV*()DP&KD BX7^
M@%L!@_UHHQB&; O#/TG['%2[EHJ8PKA/60[P*6AHG+J-3J[2>'LL[.W701NH
M"+;!X[-P $AR4[7+-=^": /7FTIR")98(@Y2M*K)K.CMB]B@M-M%:Y@:*VVD
M*XQA*Q9UPB6M?,Z^3:=J[$:(65V2YNA--9VL+%BRG.! @Z!CI@/-T>9SS.@X
MW(*'_ER"4N(J8 \HRE3 \[]#*$:ZDP)C^M;DA5NB3N;A='<!8O-H.WK2>23'
M10Q@)5K0K*Q07B[0-:;NYJQ+].D?8&:[N*PQ@+CIUVDGA1&9C&N4:F^1TQ.Z
M3B<WLD@A0X>OX]Q0= MJ!:<792-;W3]5(7DG?*CX5]%+'89SS%!8T^+C+<RT
M87AI;?+,)8;TXG,4)0M-#/H]IXXWA*95#)-A!/P?W<DX.1L80<Q19/)MES&)
M D2D4&B\?E/0\9Q3WYR6E-_2^BR_&$6)*0%YAT(*C9RX-E\RCNZJ:L3NYS0I
M05EV_7UI2WI!Y,;!!W,26M,,<L 89D^1V:+VJK_:@-E=5X4Z3TBD7-T,B=X'
M)YL.R0<H5/UP^=JA#FK@V_69<J>*!V\860JF-7U72BL@!]LC9H0FC^0;PS",
M/PB@%4@^0DWD7C"]-JY11VN5>5%/@,^ 'D> A(X-L&HL1"R&/ LL)F4Q+WQB
M6Z\+@  3>81!%_#W[T73HB<B)7:0(&-J5#$,[M=%]%"(4<D+HCM((J7EYB/*
MG>X+K1LK.KJ8="1.!AG)^7EXRN\1$W[V$!/^"C'A9P\QX3_@>;H,;3K;.A<V
M;-<;4E>!19^K*?JD43^A1AZ">M6HR);R-%7!!/+!NPN!@>L2)<5Y:"(-%]J6
M!C*@"TL]&:NCZH1#X>4.3B+BBI$ _9R?.@EY:YUFK?<U5<'2]<ITSW]'4X"H
MW^,5]_G'TXD+D R[URY8^NU-]G>ID'74!&;@B%?)&=F]H5 5MW@36[+MH[+3
MD4A':67)!9(:-%1ZRME\ 9QBV:[H6P.]@M3+F7/[]W1M(3/2@!*#DE_V:3AH
M.Z73HJH^XO,[,=TDTH"=@5GGD$=5^]KI*Z-E'6IZ3">DO2QKV#?CV(5W; I5
MP?\/;9]8;K;UE4[$ZAO0W0$M)_W?W,'NT[1*WR&8CO=(5N2[EWY11NAS97N)
M.$ZMY9HOZYQ,\!M3$K<I.LF4GDY^@C>@9O/JO41_EI6<K\/D[V!F7 .#.J.-
M'0L_HGT?+,9XMO]'NTUI"ROVU;!=MNRV<*)6)7#MV%EB1*WUI<\ .UYV["F3
M0$0*G%Y7RB<L@7D$>_+!2LG,_PC6S8P:.*7B"T;F+]I..DR+?KL$/%M<6*2&
MT*!DPW[,)2^I,$LN]IU.KBL)HM^1I!0M!GXX# L6!>^P6N_\"< Z/>:NG\>&
M^Y.OB+VM.S*<NTV#:"#4ZR2K@II4^=(00<I6N?$7R8=H ?G.4X'7"N8KSX+X
MGZ*6)?UF"^,Y&R,.2/TU.ABI<$3X^#W'O.D7)XB2K-7MT$"8<&J+ *80YZ:V
M!^P;]GD,7$W;2D\-4,G,TJQ*#=*+#BUI>/(T' E\N@F ,:9U=9TQ>4TG2"YB
MG#90/2/$5*T /+"C"\JX^&5F="@%65V!T^7S5+#;B?X;<^>*GC9UOA9TQZC\
M*:K?;:, 2.JZ'SH$B#MVAON@BSM.H<-O+]:3\L1:?6E^3[/96 =@*(<2?</9
MKTT'3WQ9$EB31<8#]S;?T.7AU =MN2'N]:0K?7M!@-!K-2(C3.SMXH'6A875
MSB08TU>'F0B!1!=BSZ)Q@;BO>D[=<N=]6"#Q* ;*2I&XP<O"V1+:U858S?G9
M8UQ_<?38+ZNSJ-QRJSX;<#E'PHJ I,21/5EH]-X0#3X0,M-,9E%"C2BF>*:O
MXD HJ(#LAW](YI$S%_+&5R^[/KK[J0$$%]>8&7@NZVX#<IIOYX70,;MH"ZN'
M1?KS2!*#:TR.:: ]I>5GYO>UK]FM1-Q72I^&QCP!7E:P6S$E.6=PQM8^2X>6
MKQ93JU^MXX!=CKR9NA^;"U6WD>TL=F^[0D(:-Q!M!/##4;MK!0HBSVK#+?BF
MDZRN-@?58A$M5VV?-!H$4[[*U"W(.'H,HV!NF@R#8?PDW9,(<DN"J6YO9:?8
M:]Z:C]99F(AMR+0ETJCW]EZ+66"$QLO>@(*;:6"V(SEJJ*G6GJI/:B!V08O2
MLB\?2G'\!NN.0,<3S2&K$5@%V:XT;KM+OFD<NT6W3W1@)-7,-'% @G&3!!OY
MPQ7_?'4CI.Z6G!4\]1D8;BDEDG8Z"=ZI.*X<>ZGHU+<^/VQF9A!Y"-AW(&N?
M\Z66< 01O?^D*FX-IT1(/E,E=84,*A2J8C79HA>X12]VMTY#02 RQ[.P5#(K
M4PFW^89B$*:M@O;NXW"N<_B&E%A:CM*7Z_'3Z$FP>EUP6#R"P8M'TQ.9>TN*
M 7?(5.<92U_D_ZV\0,1'&W0K9NRK0=+F?Y8Y5^)?<YAV)$=ES,;C+U7JLA4^
MPEF:%%4K&'QEH]H0FT7.7)Q.^N9>( XBN,NK5"(! 38]"G@JN=']3]R)8'%P
MF+SL.'F9S4P:ZV,2W('<3(,9.K(L:_AV8X"^0>]7J,L:XG03B-#_>L_?=*V4
M'$N##IZ)6)#@,GXJ/)3.!K7FV@.6[]SV\I\@_:UX&V'M&L<'.)EV5N$P*Z=Y
M_V>SWKQX&P5?_S(.8GIXRN\1$WW^$!/]"C'1YP\QT3_B>1JU+^M7BV*$*Q62
M+) NKZ+4(*_E&DUP18HOY_&H7P6^).U>WI>6@UP]7Q,X0ZXOR5S-QH(F -'8
MH#I3DSMS:4&@IO5"G%B_<=$B'9@:@K&DLT6S<CE"G!B42E:0IBI*SA"+7HDX
MN:[P+'K/CS@YS &>R+#LT.''^2I7T8GQ_D@;QDCKQA:WD@/)46)%G/1JKE?T
MH^QAGQL&*]%L."(,+.!*!+_$>WO(*>(#E)PMYPS0T+3+H.3P9^%PGBMIZ)I5
M#*^E672-,[G%(\;*@Z@X%7K+-FGLYH"* 3. W=6A[:,=:NL(CS*.#C0;\>.3
M >3>7W.RF%!<MBC[RFK?P+=KK=/-)+$9MD(\:_$]8'CQM#.4FA4_/)=_A*HX
MI8">586VC6X7L"A5X79 "VZRFGUX,S)/JTU72"F0)AM*+BMGTTDXN"C*\81O
MKYUM)WZ8N=9F]HKK&'LPYV3[Z01)K:6D) -OF".]J4]3ES/BXB]Q<J+/-BQ5
M_?5N9B:"G4/@O*I<X<!  64,ZD,6<2\5V=<)<PVC\A:M-!7J\9XDA%I:Y)PZ
MF,&]9(1G7=T,<J YVQ/GG'T-_$J<F_D1+Z7$5-I%WO8*7=5CQ?R/2(R/4[58
M'-"G!\W*%@N?0,JGT_%>[D<*KEH(]<EDW;%B*D[]*M(T\'CV8^'X<"1"1TK9
M4+ F8!YC@4)1Q<Q9'G'>CC_O+JHUP]J46:$MIO=GE7+AA:^$F(5<%P!RK>&/
M:+4G)RE&O-EV'?A:O]A$XV^KJL[_.9JD%>SODS6]U,8NND*6W6>;"%LNZ$BY
M?)*<L7HED3;=+7F-#F/@U!%_V]AZ1;JSEI"(2\PV@[[I]"#0;^DXM1 $T0NC
MGU7S#ELA_E[O.^70)R>^BQPCMNQ\7$!QK%!3ZU L=Q+N]?#@. 9IHP=SB=[:
M-3VEV#K':5ZB$:L(P![_X6\%DE3J(7,?4E8AX#C#T!TFJW,%&SVX&9A@EYS3
MYJ-&:\=]N%5Z9I$9QECR(OW[\M=#'P>1SWL1<!""6F4]I]"&!@!8[V='-TY!
M"*_LG Z"F85Z"7%".K^I\F-,'Y?NI-IOS+9BM::6%G)6FI1RF0.6K=_YCA^E
MO14PH3+1WGK,CM336*!J[)91NK$]M!"S/./*I8#CJNJ4EI:,Z"1'VZDU;KR,
M4DE&@]0QH\1)#IPR.,"UU""2-"@58/IB)S+3%BDR>1:$@8ERISC$4!6^Q 27
M^V(<U#%%<XI.#VN'VGNC9F1[.F9\9D4)R%V1FRJ;:73<X+SKTWBBY7CP+5=!
MW T;%.BY%()(14E5_Q24]U[9TDCH9,R>W9M_WZN;K$E'X5BCS_TAD3"WNXD_
MVT&(!8.JVC*C'PPQ#;I#^;Y($6?2,7NC W#+$.5W$D:1-C!:M ?W:+/*%Z@V
MD@\,'Q#P8&=M'$B_0F^V(D&WU5/P%V2_:0D?-WV/H-)=/6=@N!K)D("708"D
M!=YMWC+0I'3J(2',^ER^8*]Q[;0W?1DZR!Q%08!T/:(C,6(/RM_AQHA$ V-J
ME$]0 BE[JG&'VFK,4[[M9?0P$U_D]9JXHEW/:@T?.*6!8X!$Y[C: Q%[0L:%
M/("@E1YLZ "@G-15TN%O?0XK1YZZT3Q7B+ZAPP>\\U]9K1BJ&TAIYBAFH=6S
MMWGM<I.*HJ]LX"F1#<.R0K1]3F,B6=&S4\2GQ$"^#0?_Y "H,9#7K",U+B28
M=&WN8C5#0UVQ1?R"HJQMYZPW&A@JFBH=:&>Z&QP"XL1NZ+2A)6G)[@CZ8IN4
M5CM"B:JH\XP4QM@F0G%BQZU/^\KCQE8;,97NG2JG,>;(-K1,,6O3<N-6#0DI
M^P O#1$E"9:ZJ-!+".]7==4TW_"OURMX9YDKOJ*)&OQR:=O2I#L$+$C<]E-5
M2P/XM=,#93/7<$2S[0D *K8@Z.K;O%4#,-IDT0)1RF]Y_G&Y.S05[]U29Q,K
M&@ ;(.&A0+!Z)])0 O6B. 0:<N-*&[$YHA4W>J)(<H":>$[+R@?9@J\A%.5[
MH]0MA,3XB01RF.^H[D#23",NRC&QYM%J*Y=W%K(Y2LV4+.9QO-W#4WZ/P.CY
M0V#T*P1&SQ\"HW_$\S1JM9Z%1J/9_>-XI5%6JOUJ)?[H._2$6B.HTS]5*P#C
ME:0):*W:![-=(ZGT)V)">^K5QK$JM-71FX]GMW<*TPZ32Y*,W49BB6[O&RX[
M!#CJ5LMMV-?8MY606GC%-1BI@V%K)*YA)(]9C,4[*>?(.4;25*4+<6GO*/%[
M:PB!?4& GZD1*1.O+$=3I/+,Y&-)RQLW[_^YOX,I<Y$T430<!,'&LXVC9!/O
M2G4K&V82C<N/3<F(=TE'DGHB+KD&SIUN(TD1+IV!. -")-Q!3#JH<TH1>T$8
M/"J?=21*QT,*(S[1/2>MJ^!@O2&4<8A[M& OVW02FD5Y>'0<%;2GNNL78BA4
MN_8>4Q#['X"V#3BR6V(C5=P_2I,_:/HF7]J#OWDDA9Y'.--"D$$(T,SAS6,V
M=/KTF<L5T\(.CTRGX).]TD:.T)!\\WDX41&S#^:XW#-$4NC X$A(W'<ZV4%'
MTS2;X1#TT@79G%HL(ZT8@.7EL/A<LF#./>\58Q2I$"[GGK_H.!>PV<#5JJLG
MZ7N<F.!"H+2E"P^SPLD0F36%#X4;SF!!WD5X-8A\/?EXL"3E:V-)_MC3@R0,
MH2X,%96T#,^.I(:2^\@=3B>L''!4%][!YT?\]3G]Z+VB3WZ+NX^Y5NEFG1=;
ME["H9%CG&RT(3,IN/9/4R5YZ&ZU4HY4[H./I9"9HVYQOYUX'GE"?U$-[#4>M
M/@O9?!70P24(*[D*_?0_X[S-].Q-46TV;ON::M'>2=VZ')B\YF;<C:N/HMFH
MAQV10DEHY)2"_J&13(_6+ET'-WRPB\#'<74&E^0#I,E>IDPL:O,02#-K=/[C
MW"+3FNB <,<Z3&TD*OUUI?DVO;1*V6BD9.I6>X8QG?AN]6P7G?IJS8 %B(P8
MET3"(!]H.:!XPG< XV2 3&EVK_PQ9FRISZBD+QDU1U-VD63#@:1X,WUHQ>?I
M]1)@^"@1!<PX'&HTXY<3DD+"88^6=#DX?8534KA]0*"S:F-W68Z<&%O^5FG:
MHU9X ZE>T92Y5X'F=TAU?J,)>9H7R%5(H+9**DY-<=#FB%>;)F]"4PJZ44[%
M>"C0,<\&Q!'%C)HH5MFR"M%H@T]A(Z%IHDI367L!EB$-RT&"29B/HS2]/A=C
M\=J/5>%&I'*AS&A0Y/;DY"35L**+&I+"#75:LR*1$QRIVKZL@'-\*\YP9(0I
M(,X@9[!T"I@#4G&<)V1B("L9MRIB*3A'G(_!,@2#%1M;<&)4[Y8ANEO>C$3'
M?WC*[Q$SNGB(&7V%F-'%0\SHCWB>1NUE<,5T9#$^:;VS 3AEE52=M&(1#66/
MRKDHP7[>U;5E.-*L<HZ'JWA$R2:*K#331/ :H4]ZA/MM'";'O"H7>:9XX7DO
M:Y?,-RDU+XH G]^W9T/C":][6\V?D1PWR<*)*GRXCL3#[T2@&#I9Z-30%#IT
MAH=QPU!2L-]4+72)RRXWNC^=3."N&*DPE#%RO?R<K$ON6^6,;U_ ,*BD8(\(
M6[XQ'B@L6?I;-%D/<,[ZP=VJ0H#@:B%P=JZ<"+N%$D=Z\,Q#P2R,BQ.X @V#
M&HV2AWIZQ-!,9_0C6AFW)6L/1 6MB3T1@D9#TT7OIY!^=P>$#O&$,)S/UKM!
MF+Z$GK!E;35'4A[><S\H"5<<!+^* @Z%1TTG^JQ5Y2;W#[306D@^UV>1D'Q'
M=L'T3YW*V O,Q.:](V2G$ 9S7XA'FWWT-NB><B87N)&RII$8%(+S$E7OYD)=
MX#:LY<XZT@FDML-,)V@0AP);M6[I"G5%#:J+I+YN8\)U4J;'CVBJ8'_+/CH$
M&7@<B T4:T77N9,$0;KYKHP36MD5L)3\/34?77<T3R'8IL85%-5V86N!FEMM
M&]17E/R>7"<AU3.;JJ'WPJ$D8X1E.RP%WT\$692#!A%GCWD>H&S.H>W1:1*P
M9Q*!GO'XP(/('^IJ^QAU2=_STMY5P@J ""59A(-B/^)UC@G=4VDGS$A*+=CU
ML,[C:HS*U>K(X<^-:U(CCE<YL.'P[3V;ZEF:3J+,2V8@KIC0R8UY.(T[53!L
MJ-W_C&AH6H<BQ]M(G5K.>[VI6D%)<T5$(SFFI/?\;.J/1$D5R?T1J3P2&=5"
M1)P,[HQ4BJ -S?CD"E]\I\W,F)";;HE^,,T@3SYQN&XB$T*3WQX]V4\0D0&_
M;M^Y#4TK)0A"9R_N$A@F)2?6^]QE;.%X(N8D8,3@/BI\Y6!!/7\JX'<TV]L@
M.&?A/+9>&.>[,A)(/RKE(SPY?9G2$C,CTVZ%M >:5]3+5Z:(NA%N9%2 ZX&'
M8!+,!U43.@FW1$J&W.TP/@OT3D+: Y<X:\LCS$'[(PDT(+U-C;93LBO:8F=W
MR4-=/=>^2+6+7Q;$B+1B\$20*>7W,$NP93]1X++13-/]*>^F%*YX%M\L,B7:
MP;E;7HV-!5I9<T.FO0V?XB4T):9!TK$"N#M:F@95)'"M'>5V)/SK.@H<1I7G
M0S- 21QES(#1(MD45-!H,T+=_0$=+%>"W#N7$:\0;3F<><C;)D*Z<AL9%4[;
M)Q*6D-H%4-RLJ>J9> A[4/2?-4CPC2L)JR.8$SH1BX4P$X4. -)LX_)$[ABS
MI-2:L:$%-9UP^ P: HA_N(1=$W0B74-OQ,48HE[#88V/8W!%KN7@6AK*<9O<
MM8'@;X*1Y!7G$&>4,\+%-,+OENA]$)KULC(CSGLD4$3-;GU,6^:92V5[6W>J
M5<7XC/Y:>0A'+P6-V$$R<G0I-+;\X?6E=BG?4>QA*?3.I /[=7$#Z&*J>7K\
M T_(4@>BIM%THI55GA@Y)!R*[UG-\RJ4M,$<R>D>:U1"C",UZSN/[%SYWBH,
MFT'B )0 3< )*G'@ #V>A1/)&R2-D,4N[65 ( [CGEL]\G/$U(Q+6W=P"!Q<
M*;HD%K 6M)C4F>==R7BI!N3H((P.DZM&]2(321JVW\'.'+1&!%HH+9*Y@;=8
MOLC)D*(UF5)0SMV,W-/^DKRK78%MK4@*S+&,1U%8"PYQ/\IC/\V+CKFEZ((#
M>RHJ^AI)+&7<GLQ+DI=%!RO9>1^EP-L54@U[O7#WAY[S+8!&X?IJ=HNR9V*Z
M**G36E(/^VNS.!-(G6LNH4@/D2TU'5<<F9!WWL.EW5P=C@'1:QC-X8EI]9^M
MY=GBSN!L&/')N@,@J,$#O .1:VF(6*81BM!>2S>-4W/8ZRJ0#FSY>K0&'AMK
MR4DNO6F(_<OR.D!5.^@'46F]C]A^@N1G/+"<ET+=O V^Q.@=@(N4*]CD_?5E
M*KR#?F/5)77X+SC987J<R0!',=$$9_(HL(?U"1LX^E%EI>EOFLZ <458Q<!#
M%1F,@=%&(C\?GO)[Q%6/CQX"JU\AL'I\]!!9_0.>J.NJW]4@P@G23L;>G63J
M _2ZF$X4:RTRB;@@WRN>E^I:B5+Q?,:?X$>A':](!>;R8KR^NHD\6\$D##T5
M8;6*!H& 1=FTUF3LBI<6ZVJ,\^A5,Z\VNXCVDF#*+F@B&NYKT7D!-7AZ$;5S
MY*8=+!T9WT'P)&QV*.!@ ! 'TJ!Q/7",+HLXJ8Z/O+<KPHT4C\9N&$R6P?B6
M=SS!A0<Q%4!,T3W:@"KJ9^K0/#FT.0ZF'T%H*?!(K$;)#I@<7KH%PX+$"H7@
M9:3# 9RK84GT"@@-I&M^!M)S0.D>]U4#O?1!G>75K6DX*=4AY&E;H'ZZ(S>.
M0.0H@A>U_G0X]10.UZ"+RFE2Z(^!U\H1N"]1$&^,ZWMBN#^%;],MMPY;;\?I
M]"OK7G]NZC@X&D>-FV%S3"/.*-++H;=E%5K4C(3ZQNKD"(W'QO$^XS:LM:Q<
M;.H;3FDW8_(CCJ_ _,HUF/->.$8S]HV ?<UQHHVDB$WG@)VY>I*I)XZD.#?W
MX42O<D&#0*&>P<B0C)EM'(2 '"HJUJ1JB^C46,SD<9_L=Q_--L(:2A-W%)"Y
MIZYDWXB)/6G3B84J.JM"\V1%/,OG^494F*CG.G0 ;;XFSC=XD2O):^-8#/J)
MKJHB<^CQBO9IFRC/)SPGLYG6Z4G#NQ4VA>NEDI\#M%H?@QCE'9849W-;><1G
M#: Z'&/)<ZNKVSRC!W/J".G5]6W.O9^X+*^4$,^FSN'HTLY7F$8 $)=S(14B
M']U+C>08W/2\J((,D',7L Q5-1),B'N0LR;L\2VX=3;B[%O2EA>6:[3J;54^
M")'_P2_%X4MI7X]C$1_I&)_,$824'WLNP&@6])PM6\YDE=!(I9V/Q2Y\>,K#
M4_Y'.)R/7Y#09EWNV^0ML(L?_,]?P?]\_$7]SU_9&_S-RW>O__X]?OGQYN>W
MW_]?4$L#!!0    ( /.HJE)WB,G[=1(  .9S   .    <F%D;F5T7VDX:RYH
M=&WM'6M7XDKRN^?X'WJY.WN<LP))  54[D% 9514P'GXQ=-)&A(-24S":W[]
M5G<GD$#B:\!UYCKWS@CI[JKJ>G55=:?=_WLR,-"(.*YNF0<I,2.D$#$52]7-
M_D%JZ/72Q=3?E<V-?<V#?M#7= ]2FN?9Y6QV/!YGQKF,Y?2S8JE4RDYHGQ3O
M5)[$]I,$0<Q^/S_K*!H9X+1NNAXV%3(;9.CF?3)\VCKK*CN&'NE*GP1(<MDE
MT-"JS@>$.^]D>6.DJQ?;M<"[>D%7W;7RDKC[&!V\QVS )*FO2&F&&9+OA^VS
M>7<OOO^\:]9SL.GV+&> /9 AA51("U):V@D!2;M$B0""[YF^-7H23C&=$P,X
M2\*)SI0VR]B=<5PE"^P.<$(#C)!F<!W22P2[DX76H./03?<QMF>=>]B564>_
M@4%-"V*(9FAQ+(.XL6-82\P@Q1J:GC.-I]YOC,S =;QE!/ P!G:[WNK.^CI8
M-8F74:P!ZRD41"'%C(U@%7XB^F??TSV#5/:S_">T#HB'$860)@]#?720JEFF
M1TPOW9W:P'V%?SM(>63B9;E-9NFXK ]V_U_I-#K2B:&648=X>ZB%!Z2,)NID
M#S7K[,.M(%5OKSN?I/IQM7H)/RAY*)U^[NB<<$LG>CN?X&TPP1= R8NS4?,/
M/\>32T)JBCDD_1? *M1N"2@>3 7^;YC S&D-N.1@HVFJ9')*IK<"_-DM"05I
MYR5P2R&XU0$Q5?CK'1FX?]O#ADM> &KG$%A>OQ5O?9_!8<*CE\"0;CL:=HA[
M*]TR%\F!N.S92^#4*2V7/JS<$DF)P&5+G2+7FQKD(-4#32PC4; ]U-4'T*5%
MQJAM#;"YS1]L P&.WF,ZK^JC8)RJN[:!IV5D6B9AC?JD3)67.-0JV#==58G)
M;(1^A8ZMX0!@*5S])UZ;.I4CQQIP$RRD1<&SYI]3R(19 RJBEV.U(569J\-^
M-H+B5[!R_WJ0 I]<EBWP/]AD:A*F)Z)%J0IKCR4A&V$$I0B<)7%@_28N[T%]
M<MEEBRV0AM@*6M:8PW54\!B!564FKIKRFSWP(@<I5Q_8!N&>PT<5!<[1N=;0
M";!!-Z8599\92%<?94;@X8)AA,EA]G3V7%=I2T\G#F)3(;$K6:UY&I79XN Y
MNFPL/A^;#?RUU&4J()QPO#KV2&4^A0#2O&UI&(@R85#0LDA6A(#@H<_2*)^'
MILZ9# :YQ,T!P>[0(17?<LO0)P 6-$514&@)\+D;2$3A,X%U>C6.N;M9P@.N
M <2XS%LZEAD$]BPGU/QR'BS2& <UA+1.3&N@FT^A?9HOBWCC  ?M$2XL,=2W
MT) ]<O<0>,W]+(R'G_2_??NE'GH/#;#3U\TRHEW!=/_SE[@C[.UG[<I* .XA
MJMUI;.A]>*2 91(G5=F7*]>M9K=11YUNM=OH[&?EROI1=AJUZW:SVVQT4+55
M1XWOM9-JZ[B!:A?GY\U.IWG1>ALZOF%7@RS,LV!\/5/+($DHY$MO@/NM9'MT
MT3[W<;DV-ID7H,%'21!93)5.URUE2!="&MC>*K,0,!0,%CS2+9QHM2]C6"E_
M.1((XTM5BNG3Q65W/TLIK?Q!0@!=;S=:7=1N7%ZTNV^CV9=#QQUBTT.>!0,5
MFF[RZ8HY=-%&8F%+_8RL'NIJ9',#.@P=W=,!;6.B:-CL$U15/-HNEG+Y/T44
M-!2@<VH3VW(\M!5\)QC</'$]1$;0$SFLF:B?RYPJ&G%7%LVGNF ^ERRB:/!X
M(]Z.SGZXHO*M.QBU7VU&X=!6!40#&*>I>#J%*1 SSLPB=*4JYW@*W-Q&%.B?
M;WB+0BOY0N/92)OT=9=69#R:G<7+[)R,)F<G[9*T:ZS ]\7A357:6&T1;QLU
M327S_Y/)5F."P>0IL=0FG!F1"+O(M8E" WP5Z<!/ST7@),!$G,_KEV&@*R$&
M>%@V"/0Q#&".PJJHP&;ZW<:J&GSWZ1GKJJ=1@H1/>TBV' C5THIE&-AV(2,/
M/NTA2G?:U7\23CP/D/<])X S(HZG*]@(2)0MS[,&01R][ZE!1Q\';X=^!E;N
MD9@IP"Q=R]#5/>23E,M_2I@U4]L7)_@Q"B]%%!X4S'+ M['B8\<#AU#CA;::
MI2;H?Z=%)LZD?O-ME%^%TZ(U4IK)><1VK!'5M:C7>@:=X,:)@<?@[QZU%?^C
MIRX+*-"(!.X'"A<W]/FRE=8N6R$BVR/=(, (F3CQ@KP?J*-2;N<+9M!6X\CF
M.&E50$SG<CEA]Q\NE<.(5+IXTO2+(PK3YL=$=-(6C./O5XUF05R9B!((2%7$
M'(A+VMF5\L\4&/SC!#YQ601/>,<U+5G,-R#+09:G$0?=01#KJCH+=OEBL4;D
ML$;J83_%EL)X_8QGSLOU?!&.9]DK5>>MFC48Z"[=ID34MA%7EL^/VNVZ)O<V
M&M1L=U!C8!O6E#AK5YFH):*6E9DKS=R\LBR\J;Q5\/V'!%,%8>VNO1%Q[555
M=8CK^C_.=).(\6[]DMS_$*=*L_B]M#*W'H,<7#K=^:M9G@FNL J9[# Q0I(=
MOEOY:+3H Z_!QPNG:XW-^.G)^MU=KEWOW<EDU=.;HTY5SBP75<T^,6B9-W96
MVVAQ/KMQ\V%KQH5S"?$G^.^$L+?9N!K5&YY^\V-UT5(\_E2E5GW/(5.^],:!
MK,^F2PO2!.-&MY-SDU.EV#<']HY^DENUD"+84Q6@42J\(DYZL;M;Y6+N3X4F
M\[8#JJ;;V$!D0I2AIX]HC@\+$7$?7]Q?JE:KI!^XCRC[/\=S]XV7R?4@F9>"
M_O-741)W]USH9A!;LTR"3!9];=,PTQC2E7AS [)>#+JM$K\T&6--1=^:J/.L
M0O=D^\D5'VX&A=9TI&HKL)\P/I!>3A0^)UC,DI\N^"2?66 CEW3NCZ5)C:.J
M<WU=M0[M5:1)BSA3E?QN,;U;%(I_?GFTE:V^16'QR'* @WYET6'E(/B*N7L"
M]>XAON4 7H2NB)L;!G:#*GQFW17&M?+Z;NA"O#^%-5XCL+Y"DHJP;3L6^&.:
MN,K6!,G$L,:4![21<HH35$R?;F[T= .L'NDNN "/F"IPR+. 28.AX6&36$/7
MF"(7D@FW-V7C_0&6#.AYCF%QP*%J[A#@ /?-:=#6@ZC=&M-QM":GT^S/+:^;
M(2M+0EZ::4#.'+/N^B"E3Z^/:Q*V5[\YN@>RHYGUT/0S/S?!'U^5A(%U<Z.5
M7A_//.?L4RQ)5"2EW7Q^+]'M/1V(EHJ?$L3]2J;ZE,+LPZ0B.[2WV1X:A"M3
M7BKXRDVU.K2E27<RM\1=5#MJ(RDG9*#CVF.*?X"&'_D:WH%\00%.F_US<&K@
MV8R$<'V*->OZYYW](*U5O9?I>9>Z/2<3-(?3F:#88AZG12FDVY$]^IEFYX4,
M[_FAW+^NW'5?N2\=0OTD/9')#JW05=BYZ/62@M.2_'#X51F+7P?W:U7R9+K>
MI;(#N6DE1._S/+J85]/2EOR9?WN6_O,!'Q;PZQ90B+> INL.B?.D'1!S8$Y:
M4\/T7I^DO<(.EJC[DZPA1]+Y+>4%UN />.,"2E*,OR8LH4"/9SG$@3S)7C[^
MAD3J&C8W_+0'N/7[9#GO:JLEEU1P?GU)N$O?N^+<LGK\)\&*QC\I!G;==U$,
M7\?,'4PES\GK3 >R96S1HNQ[F.W.RF=+#[PEB9GX?LQO]X^KCC4]Z# W[]?4
MW-EFN0QS[3L6.$]J2Y931G_5:HW&T=%Z:_%).QZ^[YJ*DLPL('XM[5XWN\76
MU4FNOK."@N<BSE2%+J#@'CN>I=QOHW\+&4$01&1C!XVPD;B)B-[KQD'2H4_?
MTKB-)6S5_CB;=JZ+RJ%>6 &G(PA3%?JRYFNBD'?$RJ,%O0U"C^3SLW+QR^EP
M<E7XLII\B)T?I(YB^>A@'$VI2JO:J5>OGL'V-\D2UA1F-$V5QHX$R5.DL$HS
MC+I'8XVP8U'1 O#FANXBD"I$GA1R'X$_''L:C4%M6A7&+E))3S?Y65\:?J*\
M4 B*Q0ME-?Z"0 YMT8GN[K'J6M!99Z>$;7I*F);]&21P.FG)A_7D:P<SJ#26
MG0\,P<V\<0"W6BR.WM<@7FO$"R+^K9WH$8U@Z#$;6>,#XPU1P]K1EQ_W7W>[
MQ;4F9(\0]G0N]AL+<VZ,O4>LBV[F+MCJY@8S5GUIHT8#2R0&Y"Y@B:;%,IFA
M2U@OP.MO!]'[)'26W?!76JF,&#)C2K&/=<!-K=J$*4&+0T:Z"^/ OK&IT)(C
M5MAE"VQWF=[FH6)'=?E.D)J41^6V\.? (80--\,Y/)/R;R7.M]*/!2RABP(N
M<1_RN0YY&-+" &#DK_NSY3WTYOY"_'[(X_=Y],Z)2$.\6T8[MC=[$ S8H4EB
M*!<-YYZ+N6D495SZ^7@MZZEX/,PA@_38B,4<)Y?[% EX8GHDO4CQ^*C<IUA_
M'!Y$@X(@( C>[EV2AT/P?5HF8'DP;YL)\7DRF&E82&_""A+!&%*4+-44KASK
MT].WW7=_D3IR0B"H5I]%341%PY(18B3S#+5EMV4LJ9.0JB0HFJB;L"QX9("D
MC" %G2KM1N?ZK-M!%T?HXK+1KG:;%RW^.O11LU5MU9K5,U2[:-6;7?8Z]*(Z
MKD_V_D-8J0@%*F0*= )OX1WC,5^8*/S:(@J_+[>YL45/3DG"'G_*OHA[GY%.
M*\$JPK"4T4-P#JRD&%9/6."0!D:$Z#$JT[]K X%\#;KTPMK'SD\,G= *">.'
MAN>RE96N> ]#]NH;XBOP.784#>7$[<T-2EP&50&P/3M<$<4.H6MOZ)BZJU'2
M:-2KZ;+NH5(I(S+2<&0P6]T51[>]X,DBS0D -S< HD37;!8NUX:.0\O,_+W7
M-0?-[TU[NL VW9S=N463FC!3-C<X5T+'[);%$GH@49[+A'8+<1[ZN!H5" W4
M9 (9% 2 *O)5LZ<;1/4UDZD11%6VY1)V-M./JC8WQ&),DA6;%P4OO(PAED/N
M4+X#$%S8!!DZEG6##V;@L!>@R* G>.$K"*CR<WD1F?3\=1B8.H2WL[MLZ/$E
MBX6A07C+L+/W -G^Q^P-'M5_:QDQEFUNL/B53FO^9LI[4-]7K%:_S4*U+_.U
MJI011%YGC?:-#Q;DRGS18A>)G#=:W>!RCY/F8;/;R<RA/;6./7MI?U$$_UJH
M]*8$7^O=5<-^E6+Q</RM=(R2]?1N=$A#?-+3-*#G1"T85=I/#A:+DNDQH2$X
MO9,,/)2QT(.!4(GBOV]7Y@=BZ-6*J4K@E/@9WH2JZJ^2^!@!=<(7:O_,I4]/
M3(%Q3;Q<* C_&H1UDCK7P$+<684E%:#KSB."7$P@9^"+SP._CY%_51N[1?&6
M3$HE0<QHWH!MTT/LUO9C-Y4M:Y% %,(ZS YPT7WZ4% Z.\O_XB"2P05'B>-J
MT_]TU7FFNDBKL/LXM9"X6G0C4?E"1.[+[D-H<T2BD/\5.KLL[0&"6&D%]1QK
M$!>T(OK.,B@!*J9/M_U*M<?W,)KL_EU$+^"-3#<4@*P@FF3_2C1<7)R'Q&/(
ME<6M[PC3BM.Z#WP?^#[P?>!;]F2/;)-(\=LDZ]L&2=QY^5VW2:*W57.^[B%Z
M06,951TLZ\H>^DJ/ @&S@ZNLJ11:%F6]%-F:",;3EH^-EW=E;8]NQ,1>M+:^
M^U^;QZUJ][K])O?-_O]JS^%+./GN_L-0=UC-TYT=1'ZBVKL==RY '1I3R#>&
M="^?!</\;5F*1R;(!<J@P>)7]<E$PT:/%F0I(%:S\#MHD+@,3<_:W&#P\-#3
M+ ?<DKJN&NMO=05-_"$[0$"SRX.4]"OG8-O5>JO1W4;-5BVST@LD?.[L2)^6
M<L2X?KEG=BM\BDL87\C/5[*+7EQ:1M&+2V..2[X6_.&T_.CQRZ>.2[]:#;)N
MEA9^[NG!6\,.52U?S> X2<8_?"7)OQFY-4TG/5B[@R+<!;OR)('R=WSL\VTC
M@7=+]0? #X ? #\ _K8 GU/-R.VA"[:-Z);1&;T'YZ.XL?[BQF))(_>F)8VU
M%1B65#A+?W,8V_J@O[*N\LS?4U8\O&4'SMG-0*'?;T:^3([N5.%T?%<]UVY*
M_=W)X<ZE?"5?F,??Z]K7B=X?M^7\Z,P^ZXO-'2%+IMV>X%B:=G_8_#DRIEKU
M[FA@X)VV)?^TW#M-;XCR:5Z]^M'\=EZPSLC]-TDZ[6DW^:.O\J3XD.^-I,/C
M[_?'E]US]>=-)ULJ[IQXACYHUM2[P8^?=[6+J^)=^SR_V^B.Q>[YU.CLMB].
MQ8?K4]RHBI=GQW9.ET?:^&NM.!5/VB6A;][@NZ;=KIT7IL?_;=ZTNW53VWWH
M?)_^O+\@-[7ST_]6G:/!T.GU!F>>*)[7IA/WQI2N3DIJMGJ8-[]^:5X=''"6
M_ ]02P,$%     @ \ZBJ4N;']1LM P  Y0L  !$   !R9&YT+3(P,C$P-3$P
M+GAS9+56VW+:,!!];F?Z#ZI?.[Z1DC0$DNDD34M"+H7<VI>.L&6B099<20;S
M]Y5\@X!Q@;0\2;OGG-V5=F7:)TE(P 1Q@1GM&*[E& !1C_F8CCK&_<#\/#CM
M=@UP<OSN+5"_]GO3!.<8$;\%SIAG=FG CL U#%$+?$44<2@9/P(/D,3:PLXQ
M01R<LC B2"+ER"*U0-,Z@, T-Y!]0-1G_+[?+66?I8Q:MCV=3BW*)G#*^%A8
M'@LWTQM(*&-1BCF)D_\VHU]AX97D#Y<L8@=)'S^-$/T4?QD^15<WL'$Y@[=R
MUFPV!C_&R23L[P>/X_WA;"0N?MXG#[A/OKD?'S]^9Q=9R+;PGE$(@;H**CK&
M0GG3/8OQD=UP'-=^NNH-4IR1 5L)P71<!7</#P_MU%M 5Y#)D)-">L_6[B$4
MJ%167ER#QU1(2+T7>%^6A$5PT\Z<+Z"X$KJ?07$!]=$23B#/&K&)K1P*WW +
M8"S,$811"0Z@&*:BN2,%FXYK[I44P>4J7!FKH::<14A4$C)7!:U_=GU7,CCT
M*9*Z1U.DTW3UG!$4(BK/&0_/4 !CHE+Z'4." XQ\ TC(1TCJIA,1]%"M5M&W
MD%*FVEM-6&[1MBC"JG^5X4U;7W2+,X+N5-9 +]1<52EKEWW*U,-@ .QWC&RI
M-91BJN*C %.<ALKGQP6FGI98%Z66*:5M+X,7)&*!_!MZG*XCCH3BI;GWE"$G
MYI U) \2+R;;<>:I5%)R0W%&\U,K9J2/ I#.5DO??,<06+]M1FY[YBCH&-RG
MTBPNYY<JS5(]44"T=,ULI2>_?!IYX$("<F]%967VE0B+$)=8M>?"@&>I8ZGI
MMPMA@(XC#&#_BY()'&Y;LJ(@\A]K[6G]Q2+S\;#G\Y'OEV>HK<IE7 *Z,HIU
M+V/VIO>8ETK54/3.+'BF-IEN0STD5B+\>:;;)#$_@>V2*'@[)+'F?:Z*+];!
M]2)MH4V#UK[SM:$KF38B4A06<ZZU2SJK7X57Y).*[9#0BVOV);>UD)9VM$[=
M_?R-F>[%3LWAL9A*/MNF018IQ6:W1EG^PF]V*04KNQ#]T7]%<U3_9]@UD?6M
MT;8S3;7\ U!+ P04    " #SJ*I2_(V2 OH*  !^A@  %0   ')D;G0M,C R
M,3 U,3!?;&%B+GAM;,V=76_CN!6&[POT/[#N30N,XW&";9'L9!<93[(P-IND
ML6>V[:)8T!+C")')@)(3^]^7%$59HG@D)45)SL6,1WP/]5)\3%)?QY]^W&U2
M]$)XEC!Z/IH>?1PA0B,6)W1]/OJZ&%\L9O/Y"&4YIC%.&27G(\I&/_[PQS\@
M\>?3G\9C=)60-#Y#7U@TGM,']CVZP1MRAGXBE'"<,_X]^H;3K=S"KI*4<#1C
MF^>4Y$04J!V?H>^._H[1>#R@VF^$QHQ_O9]7U3[F^?/99/+Z^GI$V0M^9?PI
M.XK89EA]BQSGVZRJ[./N8_E'A7]*$_IT)O]:X8P@<;1H=K;+DO-1;;>O)T>,
MKR?''S].)__\Y7H1/9(-'B=4'K6(C'24K,46-ST]/9T4I5K:4NY6/-7[.)EH
M.U7-HC3IT-><9,E95MB[9A'.BT[OW0T"%?)_8RT;RTWCZ?'X9'JTR^*1/OC%
M$>0L)??D 17-/,OWSP*D+)$<C,IMCYP\V,VDG$]D_(22-<Y)+'=T*G<T_9O<
MT9_+S==X1=(1DDJ!!]BNTT9=9=#$M=D[PA,67]+WN3:C/=D7WQV>_P\-J,<[
M;\*2Y3A]E_EZI'/;-^1]1_P0Y_Y(BU&>O.](UR+_+[;SMN4W'U[[<4WEQFOQ
MJ6&1['(Q?Y%8FY15=(S Q1Z*B:&LNZJ=18UZ4SF:,]YN>R;J+>K,2'2T9B^3
MF"2B[N.I_#"6'XIFB__\/F-B'7"QRG*.HUS75#3C?&0IGYB6I/*":U^81SV-
M*Q63B(FIZ3D?I^HPJO 'SC;6W9:M9I;"W]-5%:\.B]@%8+0AXR1C6QZ1-_5*
MW2UTE$I'FU0HY(**T/'7Q>B'0H-^TZK_?)H<:G'0T6()M-T0FB]%C986-(M=
M=;/-E.[E>ED0G6PQ9/:QEB"I<=S!%V+'L=SY58K7%OM&N:LNMMK2?=PH#**3
M;8[,7JXT2(I\=?,7DD4\>9;+^:YV-&3..]UBLM7W-4U8"+2-P234M)X&]GNR
M3N34(BW(\ULB-W8,8X#>]=#?:=N<"ZSB(* 9XA"<+>I!J(KRQ-$%I5N<WI-G
MQKOP:<I<4V,S:<)2UP3%B,48B(;2(B7V1,0_MN*,G?!TWPM%2^F:"\"JB88A
M"XH.NS<0D$KNEY$EQS1+Y #6"TE;ZOQT S#;.O4P=$%Q IB#3TDJO5]2%H\D
M3>7= $S[!Q2;V#4ML&&3E[8R*&) >R S100J0\+!YO)%KL[%,FE@8VMZG_"T
M;'?Q4XF#1<AT.)"B(@S).$\DU6Y#]##44KJF![!J<F/(@B+&[@UD1<E1H?</
MR26-!R%2Z?P 8MBTXU&* H2CZ:P/#:'V"<95DD4X55ZNQ+:LHWD6K6M 0+LF
M)"UA4*! [D!85(!FI@CQ"LR_".;#<*DI_<#2LFI'I9(%"(KIK0\3J?<"R6S+
M><,U/./ 4F<W97O,5O=G 5T0H/28:]VU5?(&*)YFH$N:)_E>/DUWL]VL"+<T
MKBUQQ09D3C-AE@?! F#*9$#)D-0A)?32\_HN <WE0XQ@<TR96P+L)IL4-#4!
MD6 U!M!PT!;/E'HA8B9&)H[3.8W)[F>R!]O5TKEE K#9A,(0!42%W1F 12E&
MA1H)N1<P[GBRP7R_2**>J:(M=(L&9+3)AJD*" [ &D!'J4:+^<SG3++$NWDL
M0$T>$O4\> \EH-XM+#VVF\P XH#0Z78($"2"4#/*)TAS&C'^S&J/.\S85@R
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MMB((%$!;)@<'(=)*QQ#<<2(A)*(CBI< 96(A?OOP8)WMN\2NH.@WK.& E4%
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M;F5T7V5X.3DP,BYH=&U02P$"% ,4    " #SJ*I2=XC)^W42  #F<P  #@
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7;%!+!08     !@ & '\!  !(H0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
